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Abstract  
 
Heparin (Hep) and heparan sulfate (HS) have been shown to possess anti-
coagulative properties, inhibit smooth muscle cell proliferation, moderate 
inflammation and control angiogenesis by stabilization and potentiation of growth 
factors (GF).  These properties are potentially very useful for the treatment of 
cardiovascular diseases, especially when delivered as injectable hydrogels that can 
form in situ.  This project focused on developing Hep and HS hydrogels for localized 
GF delivery. 
 
Hep and HS were acrylated, characterized and crosslinked with PEG tetra-thiols, 
either directly (10m% Hep/HS-Ac, Type 1) or by copolymerization with 20PEG8Ac or 
20PEG8VS (4m% copolymer; 1.5% Hep/HS-Ac) to form degradable (Type 2D) or 
non-degradable (Type 2N) gels, respectively. Gelation times, viscoelasticity, swelling, 
mesh size, Hep/HS elution and activity, as well as GF incorporation and release were 
studied in vitro. Type 2D gels with covalently incorporated (CI) Hep and GFs were 
evaluated in vivo as ingrowth matrices in porous polyurethane (PU) scaffolds for 
healing response in a rat subcutaneous model.  
 
Forty percent acrylation was readily achieved and Type 1, 2D and 2N gels formed 
after approx. 4, 7 and 3 minutes (37 °C, PBS, pH = 7.4), with storage moduli (G′) 4-5 
kPa, 6-8 kPa and 9-11k Pa, respectively. Type 2N gels had faster gelation times and 
higher G’ than Type 2D gels due to the higher relative reactivity of VS towards 
Michael-type addition reactions than Ac. After rapid initial swelling caused by 
equilibrium water uptake, Type 2N gels were stable for more than 6 months, while 
Type 1 and 2D gels showed increasing swelling ratios, which resulted in 
disintegration after 22 days in the case of Type 2D gels due to hydrolysis. Gel 
properties of Type 2 gels were not significantly influenced by the addition of non-
covalently incorporated (NI) or CI Hep/HS.   
 
The sustained Hep/HS release from Type 1 and Type 2D CI gels can be described 
by zero (R2 ≥ 0.96, 0.93; Hep-Ac, HS-Ac) order kinetics, while Type 2N CI gels 
followed first (R2 ≥ 0.90, 0.84) order release kinetics due to the absence of the 
secondary release mechanism. Conversely simple incorporation led to release of 
essentially all the Hep/HS within the initial two days.  Anticoagulative activities of Hep 
and HS were retained in the original form, after chemical modification and after the 
vi 
 
incorporation and release from Type 1 and 2 gels. Type 2D CI gels achieved 78% 
(PEG-Ac/SH/Hep-Ac) and 51% (PEG-Ac/SH/HS-Ac) more bonding of GF than in 
Type 2D control gels (PEG-Ac/SH). GF release from Type 2D CI and control gels 
followed zero (R2 ≥ 0.91, 0.99; Hep-Ac, HS-Ac) and first (R2 ≥ 0.96) order kinetics, 
respectively.  
 
Gel incorporation limited tissue ingrowth after the first week of implantation, due to 
gel presence, while scaffolds without gel allowed full infiltration during this time.   
After 28 days the degrading gels were completely displaced by tissue. The use of 
Type 2D control gels in scaffolds resulted in the formation of fewer blood vessels 
than scaffolds without gel due to the gel presence causing a delay in tissue ingrowth. 
However, the capillary relative to ingrown area in scaffolds containing PEG-
Ac/SH/Hep-Ac gels with and without GF were respectively 119% and 50% higher 
than scaffolds without gel. The controlled and localized delivery of CI Hep from Type 
2D gels thus overcame the ingrowth inhibition, led to a significant and marked 
increase in angiogenesis in vivo and was even more profound when pro-angiogenic 
GFs (VEGF) were additionally delivered.  
 
These Hep gels are potentially very useful for vascular graft applications where their 
potent anticoagulative properties could help retain patency while the GF binding and 
anti-inflammatory properties facilitate angiogenesis and healing. For cases where 
strong anti-coagulation may not be as desirable (such as myocardial infarction 
therapy) analogous HS gels may be more suitable. 
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peptide chain 
proteoglycan A compound consisting of a protein bonded to glycosamino-glycan groups, 
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thrombin An enzyme in blood plasma that causes the clotting of blood by converting 
fibrinogen to fibrin  
thrombomodulin  An integral membrane protein expressed on the surface of endothelial cells 
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1 Introduction 
 
Since the discovery of the anticoagulative properties of heparin (Hep) in 1916,1 the 
polysaccharide has been shown to possess numerous other advantageous 
properties. These include inflammation moderation, cell adhesion promotion and 
smooth muscle cells proliferation,2–4 and the ability to control angiogenesis through 
the sequestration and potentiation of growth factors (GF),5,6 which is the main focus 
of this project. Local, controlled and sustained GF delivery is known to induce 
localized growth of healthy vessels and to prevent undesirable side effects adverse 
to healing.7–11  Therefore the incorporation of Hep into a suitable delivery device that 
can elicit specific biological responses, such as survival, proliferation and 
differentiation, is of interest in regenerative medicine.12 
 
Hydrogels have proven themselves useful for drug delivery applications and several 
delivery routes have been developed over the years. Some of the favourable 
properties of hydrogels as controlled release systems include their drug protection 
ability, physical integrity and network structure provided by the crosslinks. The 
particular interest in this work was to synthesise spontaneously forming Hep eluting 
hydrogels, which have the potential to improve healing in the treatment of 
cardiovascular diseases, the second-biggest killer in South Africa and the leading 
killer worldwide.13 However, in some instances the GF binding and anti-inflammatory 
properties of Hep are more important than its anticoagulative properties,2 and 
therefore the use of a less antithrombotic agent, heparan sulfate (HS), was also 
considered.14  
 
The remainder of this chapter will be dedicated to reviewing literature pertaining 
Hep/HS hydrogels, formed through Michael-type addition reactions in particular, for 
GF delivery, as well as their potential use in cardiovascular applications.   Finally, the 
aims of the thesis together with novelties of the project will be presented in more 
detail. 
 
1.1 Glycosaminoglycans 
 
Proteoglycans and glycosaminoglycans (GAGs) are components of the extracellular 
matrix (ECM) and interact with a variety of molecules and ligands. These interactions 
are associated with coagulation, growth, inflammation, fibrinolysis and lipolysis.15–17 
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Since proteoglycans are formed by GAGs covalently attached to core proteins, their 
major function depends on the GAG component of the molecules. Most GAGs have 
the ability to stabilize GFs, cytokines and chemokines; signal molecules in response 
to cellular damage during wounding/infection; and regulate enzyme activity.7,18–20  
Glycosaminoglycans are negatively charged molecules constituting of long, 
unbranched heteropolysaccharides with alternating disaccharide units (dimers) and 
contain either of two modified sugars (N-acetylgalactosamine or N-
acetylglucosamine) and uronic acid (such as glucuronate or iduronate). Hyaluronic 
acid (HA), dermatan sulfate, chondroitin sulfate (CS), Hep, HS, and keratan sulfate 
are GAGs of physiological significance, with specific focus on Hep and HS.  
 
1.1.1 Introduction to Heparin and Heparan Sulfate  
 
Heparin and HS are highly sulfated, anionic and heterogeneous GAGs of which the 
polysaccharide backbones constitute linear, alternating sequences of 1→4-linked 
uronic acid (I) and glucosamine (A) residues (as summarized in Table 1).21,22 The 
backbones can be represented by  (I-A)n, where n varies from 10 – 200,23 and the 
amino sugars of the residues may be N-acetylated or N-sulfated (of which the latter 
substituent is unique to Hep and HS).2,24 Although Hep is polydispersed in nature, the 
major disaccharide repeating unit consists of iduronic acid 2-sulfate (1→4) 
glucosamine-2,6-sulfate (IdoA-2S – GlcNSO3-6S), that accounts for at least 85% and 
70% of the dimers in Hep from bovine and porcine intestinal mucosa, respectively 
(see Fig. 1).25–27 Heparan sulfate is similar in structure to Hep, except that it is less 
sulfated, contains higher acetylated glucosamines than Hep and the relative 
proportions of N-ester and N-sulfate content of the iduronic and glucuronic acids 
differ between Hep and HS.14,28 
 
           
Figure 1: Major disaccharide repeating unit of Hep 
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Table 1: Abbreviations and chemical formulae for residues forming Hep/HS (red 
indicates the position(s) sulfated) 
Compound Name Structure Specification Abbreviation  
Uronic Acid (I) β-D-glucuronic 
acid  
 
 
 
R1 = H 
R1 = SO3- 
GlcA 
GlcA-2S  
 α-L-Iduronic acid  
 
 
R2 = H 
R2 = SO3- 
IdoA 
IdoA-2S 
Glucosamine (A) N-sulfo-α-D-
glucosamine 
 R3 = R4 = H 
R3 = SO3-, R4 = H   
R3 = R4 = SO3- 
R3 = H, R4 = SO3-   
GlcNSO3 
GlcNSO3-6S 
GlcNSO3-3,6S  
GlcNSO3-3S 
 N-acetyl-α-D-
glucosamine 
 
 
 R5 = H 
R5 = SO3- 
GlcNAc 
GlcNAc-6S 
 
Heparin is abundant in the liver and granules of mast cells lining blood vessels, while 
HS is found in the ECM and on the surface of most eukaryotic cells.29 Their biological 
effects depend on specific and nonspecific ionic interactions mediated by charge 
density/distribution, sequence composition and molecular size. The acidic nature and 
extremely high negative charge of Hep and HS mediate their biological roles as 
multivalent binding agents for many proteins.30–32  More than 100 proteins with 
heparinoid-binding domains have been identified in various studies, such as proteins 
involved in coagulation (primarily antithrombin III), fibrinolysis and lipid metabolism, 
various GFs, ECM proteins related to cell binding (laminin, fibronectin, vitronectin),33 
proteins associated with osteogenic differentiation (bone morphogenetic proteins and 
pleiotrophin), the cell-adhesion molecule protein family,34 as well as mediators of the 
immune response (pro-inflammatory cytokines and chemokines).2,35  
 
1.1.2 Anti-thrombotic Properties of Heparin and Heparan Sulfate 
 
The anti-coagulative properties of Hep are mediated through a pentasaccharide 
sequence (see Fig. 2) contained in approximately one third of the chains. This 
sequence is known to bind antithrombin (AT) III which subsequently complexes 
thrombin.28,36–39 The middle residue of the pentasaccharide, 3-O-sulfated 
glucosamine (in red), is key to high-affinity binding of AT III.28  
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Figure 2: Pentasaccharide antithrombin-binding sequence. The residue in red marks 
the typical 3-O-sulfated glucosamine residue and the circled sulfate groups are 
essential (full circle) or marginally essential (dotted circle) for high affinity   
 
Blood coagulation is initiated by tissue factor exposed during vascular injury and 
leads to the generation of thrombin. Since thrombin is known to convert fibrinogen to 
fibrin, activate factors V and VIII (key cofactors in coagulation) and activate platelets, 
which leads to generation of more thrombin, tight regulation of thrombin activity is 
essential to prevent excessive thrombosis.40 Two anticoagulant pathways exist to 
regulate thrombin, namely the protein C and AT pathways. The protein C pathway is 
initiated when thrombin binds to thrombomodulin and converts it from a pro-
coagulant enzyme to a potent protein C activator.38 The AT pathway, on the other 
hand, inhibits thrombin and other clotting enzymes in a slow, progressive fashion 
through interaction with AT III.28,38 Once Hep is released, in response to injury, it 
enters the serum and its pentasaccharides complex AT III. This results in 
conformational changes at the reactive centre loop of the AT and enhances its 
reactivity with thrombin, which has shown to accelerate the rate at which all the 
serine proteases of the coagulation cascade are inhibited by two to three orders of 
magnitude.28,38,41  
  
Although there are many structural and functional similarities between Hep and HS, 
an important difference lies in their anticoagulative activities. Similar to Hep, HS 
binds AT III via a unique pentasaccharide sequence containing the 3-O-sulfated 
glucosamine residue, but the pentasaccharide only comprises one to ten percent of 
the glycosaminoglycan side-chains. Heparan sulfate is therefore known to be less 
antithrombotic than Hep.  Hoppensteadt et al. (1990) confirmed this with a rabbit 
model of stasis thrombosis which had shown that a five to ten time’s higher dose of 
HS was required to produce an equal antithrombotic effect as Hep and, regarding the 
haemorrhagic effects, Hep had also shown much stronger platelet interactions than 
HS.14,42,43 However, an investigation by Weitz et al. (1996) had shown that HS is not 
completely non-antithrombotic.38 They generated mice deficient in 3-O-
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sulfotransferase-1 (an enzyme responsible for 3-O-sulfation of the glucosamine 
residue within the pentasaccharide sequence) and showed that the ability of HS to 
bind to AT was only attenuated.28,38,44 
 
Even though Hep is a common antithrombotic agent, there are bleeding side effects 
associated with its use in certain biomedical applications - especially when 
administered at high doses to fully exploit the heparinoid’s anti-inflammatory and GF 
binding properties.14,28,45 Due to the reduced amount of AT binding pentasaccharides 
present in HS, little to no bleeding side effect has been observed at HS dosages in 
the antithrombotic range.14 Heparan sulfate will therefore be used as an alternative to 
Hep to develop solutions to applications where anticoagulation are not needed or 
may even be detrimental, but which still have the need for GF binding and anti-
inflammatory properties. 
 
1.1.3 Growth Factor Binding Properties of Heparin and Heparan Sulfate 
 
Heparin and HS have also attracted a lot of research attention due to their ability to 
bind GFs, potentiate and retain their activities, stabilize their active conformations, 
and protect them from immediate clearance, degradation or thermal/proteolytic 
inactivation and limit their activity to cells liberating the GF during proteolytic 
remodelling of ECM.46–53 Interactions between Hep/HS and GF’s occur by shape 
recognition, as well as electrostatic attractions between N- and O-sulfated residues of 
Hep/HS and the lysine and arginine residues of the GFs.16 To date Hep has shown 
high specific binding towards fibroblast GFs (FGF), vascular endothelial GFs (VEGF), 
platelet-derived GF (PDGF), glial-derived neurotrophic factor (GDNF), human growth 
hormone and transforming GFs beta (TGF-β).54–59 Heparan sulfate has also shown to 
modulate the binding and signalling of GFs, including FGF, VEGF and heptocyte GF 
(HGF).60,61   
 
1.1.4 Need for Controlled Heparin and Heparan Sulfate Delivery  
 
For certain tissue engineering and biomedical applications Hep/HS delivery should 
be localized and controlled to maintain optimum Hep/HS concentrations in the target 
tissues and minimize side effects.  Although Hep/HS can be introduced to the blood 
circulation through several ways, such as directly via intravenous injection or via 
transdermal or oral routes (secondary) from where the drug is absorbed into the 
circulation, its delivery should be controlled to obtain the optimal concentration (not 
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too high or too low) at the area of interest. Furthermore, when Hep/HS enters the 
circulation many different cells and organs accessible to the blood system are 
exposed to unnecessary treatment.  It is therefore important for certain applications 
that Hep/HS should be administered by means of a drug delivery system which 
releases it over a specified period of time and at a rate which is determined by the 
needs of the body. Since drug delivery using hydrogels is well known for meeting the 
demands of both controlled and local release, these will be discussed for Hep and 
HS release. 
 
1.2 Hydrogels 
1.2.1 Introduction to Hydrogels and Applications 
 
Hydrogels are insoluble, three-dimensional (3D) polymer networks that are swollen 
by and capable of absorbing/retaining a significant amount of water.62 Due to the 
ability to control certain properties of hydrogels they are used in contact lens 
production, controlled release matrices, bio-adhesives and various other biomedical 
applications.63,64 Since mechanical, solute permeability, elasticity, swelling, and 
hydrophilic/hydrophobic properties of a hydrogel can be tailored by choice of 
polymers and synthesis method,65 it is possible to create gels that fulfil the demands 
of biomaterials with physical integrity and network structure suitable to be used as 
wound covers, implant coatings or materials that mimic in vivo functionality.66,67  
 
In tissue engineering, hydrogels are also increasingly being used as cell carriers 
because of the structural and mechanical similarity between the ECM and a highly 
swollen hydrogel network (consisting of over 96% water).68 Since these porous 
hydrogel scaffolds permit circulating cells to infiltrate them and allow diffusion of 
respiratory gases, nutrients and therapeutic agents through the gel, they are optimal 
vehicles for drug delivery, cell implantation, and regrowth of new tissue.69  Hydrogels 
are particularly conducive to releasing water-soluble drugs due to their drug 
protection ability, rapid mass transport and highly predictable degradation (if tailored 
to be) conditions.70 Controlled release mechanisms include diffusion, swelling, 
chemically controlled systems as well as environmentally responsive systems.    
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1.2.2 Polymeric Building Blocks and Crosslinked Networks 
 
Since hydrogels are created when a sufficient number of crosslinks form between 
polymeric building blocks, their properties are mainly dependant on the nature 
(natural or synthetic), functionalization and geometry of polymeric building blocks, as 
well as the nature of the crosslinks formed between these polymers. This should all 
be taken into account when developing hydrogels suitable for localized and 
controlled drug delivery.   
 
1.2.2.1 Natural and Synthetic Polymers 
 
Natural polymers used as building blocks for hydrogel formation contain inherent 
biological properties, such as charged groups, signalling peptides and/or other 
functionalities, which make them useful for many tissue engineering 
applications.16,71,72 These polymers include several polysaccharides (alginate, 
chitosan, collagen, dextran, fibrin, HA, Hep and HS) and proteins (collagen, fibrin, 
gelatine).46,65 Moreover, polysaccharide-based hydrogels are known to be non-
cytotoxic and biodegradable.70 However, due to variation in composition and 
substitution pattern between different batches and polymer sources, hydrogel 
formation through natural polymers often deliver unpredictable results and potential 
risks of infectious pathogens and immunogenicity (especially in the case of animal-
derived substances) exist.73   
 
Synthetic polymers, on the other hand, offer greater control over the material 
properties of the gels and good repeatability. To date a wide range of synthetic 
polymers have been used to create hydrogels for utilization in cell scaffolds and drug 
delivery devices, including polyacrylic acid, polyethylene glycol (PEG), polylactic 
acid, poly-N-isopropyl acrylamide, poly-N-vinyl-2-pyrrolidone, poly-N-
isopropylacrylamide (PIPAM) and polyvinyl alcohol (PVA). 52,65,74,75 In recent studies, 
natural and synthetic materials have been combined to form scaffolds providing not 
only mechanical stability and structural support, but also bio-functionality.76,77 With 
this broad register of choices gels can be created with very specific properties that 
fulfil the strict demands of biomaterials.65  
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Polyethylene Glycol Hydrogels 
 
One of the most studied and widely applied synthetic polymers for hydrogels is 
polyethylene glycol (PEG), prepared by polymerization of ethylene oxide.68,78–80  Due 
to its widely reported low immunogenicity, biocompatibility, hydrophilicity, 
platelet/bacterial repellence and resistance to protein adsorption, it is often used in 
biomedical applications.62,74 It is also non-reactive towards proteins, receptors and 
other parts of cell membranes and generally has a very low reactivity toward tissue 
due to its extensive interaction with water.68  Moreover, hydrogels formed by PEG 
have been approved by the Food and Drug Administration in the United States for 
various medical uses such as valves, biosensors and surface mono layers in 
microarray devices.77   
 
Although PEG by itself is nonreactive, the abundant hydroxyl pendant groups on the 
chains can be substituted with various reactive, functional groups that are able to 
form crosslinks and insoluble networks.81 Polyethylene glycol functionalized with 
acrylates, methacrylates, vinyl sulfones, amines, sulfhydryls, maleimides, N-
hydroxysuccinimide (NHS) esters, aldehydes and carbodiimides, among others, are 
well documented.6,12,47,68,80,82–84 The PEG geometry is also important to obtain desired 
gel properties and to facilitate crosslinks, since it has an extreme effect on the 
swelling, mechanical strength, solute permeability and drug diffusion properties.85–87 
Common geometries of building blocks include linear, branched, star-shaped and 
dendritic structures.  
 
1.2.2.2 Physical and Chemical Crosslinks 
 
The mechanisms responsible for producing the crosslinks between the building 
blocks categorize hydrogels into either physical or chemical gels, while drug 
incorporation into the crosslinked network can also be of physical or chemical nature. 
Physical crosslinking occur either due to non-covalent interactions between polymers 
or as a result of entanglements between dynamic macromolecules. These gels form 
by crosslinking polymers functionalized with charged groups with species of the 
opposite charge,  associating blocks to minimise contact with the surrounding media, 
hydrogen bonding, metal-ligand interactions, or through stereo-complexation.62,88  
The connections are generally electrostatic or solvent induced and reversible, 
allowing systematic re-establishment of the non-covalent bonds.89,90 Chemical gels, 
on the other hand, are fabricated by the formation of covalent bonds between 
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functionalized polymers.91 These gels are stronger, easier to adapt/modify and have 
greater mechanical properties than physical gels.  
 
Delivery of drugs incorporated physically into gels (physical of chemical) constitutes 
systems where the drug is stored or dispersed within the gel and release is controlled 
by the design of physical parameters, such as crosslink density, degree of swelling 
and degradation rate. The release of drugs chemically incorporated into gels is 
dependent on the breaking of covalent bonds between the drug and hydrogel 
(through hydrolysis, enzymatic digestion or reduction of disulfide bonds) and is 
therefore potentially much more controlled than when physically incorporated.  
 
Well known methods used for the chemical formation of covalent PEG crosslinked 
networks, which are capable of local, controlled drug delivery, include free radical 
polymerization, amide coupling reactions, enzyme-catalysed reactions, Michael-type 
addition reactions, thiolene chemistry and other click chemistries.92,93 The focus of 
this thesis was however on Michael-type addition reactions. 
 
Michael-type Addition Reactions 
 
The Michael-type addition reaction (also known as 1,4-nucleophilic addition reaction) 
is a spontaneous reaction between α,β-unsaturated carbonyl compounds (Michael 
acceptors) and nucleophiles (Michael donors) which does not rely on radical 
chemistry.94 The conjugating feature of the double bond renders the terminal carbon 
electrophilic and liable for a nucleophilic attack.95 The nucleophiles deprotonate and 
react with the electrophiles, whereafter proton abstraction from the protonated 
solvent occurs.  The reaction mechanism is illustrated in Fig. 3, an example of 
thiolated PEG (nucleophile) reacting with an α,β-unsaturated acrylate (electrophile): 
 
R
O
O
-S PEG SH
R
O
O-
S PEG SH
R
O
O
S PEG SHH
+ +
H+
Figure 3: Reaction mechanism of Michael-type (1,4 nucleophilic) addition reaction 
 
Michael-type addition reactions hold many potential advantages over other gel 
formation chemistries: hydrogels form spontaneously at physiological pH and 
temperature (pH = 7.4 and 37 °C), without the need for initiation by chemical agents 
or radiation and without producing leaving groups or undesirable side-
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products.7,12,23,96 In addition, these gels have the ability to form in situ by preparing an 
admixture of two components and injecting it directly into the treatment area, in close 
contact with biological molecules or tissue.69,80 This allows the gels to conform to 
complex shapes and sizes in vivo, alleviating the need for further manipulation, and 
allows large amounts of material to be delivered through minimally invasive surgery. 
Since biological molecules (such as proteins, drugs and living cells) can be safely 
encapsulated by in situ forming gels73,97 and the physical properties of the gels can 
be varied by functionality, molecular weight and crosslinker type, drugs can be 
released from the gels, with or without gel degradation.80  
 
1.2.2.3 Degradable or Non-degradable Crosslinked Networks 
 
Depending on the nature of the crosslinks formed between functionalized building 
blocks the resulting gels may be degradable or non-degradable, while the drug 
incorporation can also be of degradable or non-degradable nature.  For many in vivo 
applications it is desired that the applied hydrogel degrades, since shorter exposure 
to the gel will lower its risk to cause a long-term inflammatory response. While acting 
as a temporary, mechanical 3D support for cell growth,62 certain PEG gels can be 
degraded and the products dissolved into the circulatory system, whereafter it can be 
cleared via renal and hepatic pathways.51 Although degradable gels decrease the 
occurrence of long-term inflammatory responses, the degradation process and  
resorption into the body can also initiate an inflammatory response.80,98,99 Gel 
degradation through hydrolysis is therefore preferred, since it can be designed to 
occur over days to months, depending on the desired application.  
 
There are instances, however, where more persistent gels are required and therefore 
injectable, non-degradable gels are developed which can act as mechanical support  
during  heart remodelling (for example).100 Our group applied such hydrogels in a rat 
infarction model in order to improve pathological remodelling in the early healing 
phase.80 Although it successfully led to an increase in wall thickness and reduction in 
wall dilatation, a substantial inflammatory response was caused by the material. Gels 
that are able to release drugs over an extended period of time to influence the body’s 
response to their presence were therefore required. Degradable and non-degradable 
gels suitable for drug delivery were therefore developed through Michael-type 
addition by Hubbell and co-workers,47,68,101–105 and ever since several researchers 
have adopted and developed the methodology to obtain variations for a variety of 
applications.81,86,94,99 
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1.3 Growth Factor Delivery 
1.3.1 The Role of Growth Factors in Angiogenesis 
 
For many tissue engineering and biomaterial applications, in particularly 
cardiovascular tissue regeneration, treatment should ideally include the stimulation of 
angiogenesis. Angiogenesis is important for many physiologic processes, such as 
wound healing, tissue/organ development and female reproductive functions. The 
outgrowth of new capillary blood vessels from existing micro-vessels is however 
extremely complex and regulated by more than twenty known cytokines that appear 
in complex series. The process begins with secretion of GFs, followed by emergence 
of proteinase activity and the breakdown of the ECM (i.e. plasminogen activators; 
matrix metalloproteinase enzymes, MMPs; tissue inhibitors of MMPs; heparinise; 
chymase; and tryptase) and parent capillary basement membrane, which in turn 
cause further ECM-bound GF release.106 Consequently endothelial cells migrate into 
the matrix to form capillary sprouts, which grow by continuing endothelial proliferation 
and organize into tubules to form a lumen. Contiguous tubules anastomose to form a 
new basement membrane which finally result in mature micro-vessels.107  
 
Neo-vessel formation is crucial for regeneration of lost or diseased tissues, to ensure 
a functional vascular network for adequate integration into biomaterials and/or tissue 
engineered constructs.108–112 However, a large obstacle for tissue regeneration is that 
the innate angiogenic response is either too slow or inadequate to sustain prolonged 
cell survival.113 Many researchers have therefore concentrated on enhancing 
angiogenesis by the administration of molecular regulators of angiogenesis, such as 
genes, recombinant proteins or factor-overexpressing genetically engineered cell 
transplants. Recombinant proteins include prototypic angiogenic proteins such as 
GFs, which are the focus in this project.  
 
Every step of the angiogenic process is regulated by a balance between stimulatory 
and inhibitory cytokines, of which the most important are the prototypic angiogenic 
GFs, namely vascular endothelial GF (VEGF) and acidic/basic fibroblast GF (aFGF, 
bFGF).112 Preclinical and clinical investigations have shown that the therapeutic 
delivery of angiogenic GFs through bolus injection (intra-arterially or directly into the 
sites of ischemia) and by sustained release from polymeric implants, could improve 
regional blood flow.62,114–118 It has however been seen that serious complications can 
result from bolus delivery of high doses of GFs, such as severe vascular leakage into 
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the circulation or ischemic zone, which can lead to severe nitric oxide-dependent 
hypotension or edema, respectively.119,120 Moreover, GF overdose can induce 
formation of highly fenestrated and non-functional capillary vessels due to the 
unregulated exposure of freely diffusible GFs, while the sustained exposure can 
result in malformed vessels.121–123 On the other hand, early withdrawal of GFs can 
lead to ablation of new, immature vessels and prevention of lasting tissue 
vascularization.  A further disadvantage of bolus injection is the short half-lives of 
GFs in the body -  if delivered without stabilization the GFs diffuse rapidly, undergo 
proteolysis and consequently lose their bioactivity.124  
 
1.3.2 Controlled Growth Factor Release 
 
Controlled GF release systems have therefore been developed to avoid burst release 
and provide sustained exposure to low GF concentrations, which can support the 
localized growth of new, functional and lasting vasculature while preventing 
undesirable side effects adverse to healing. Since the ECM is known to store 
angiogenic GFs, regulate their release, localize their activities and prevent their 
degradation, biomaterials that share functionalities with the ECM are favourable to 
develop release systems in promotion of tissue repair and new tissue growth.62 To 
date many polymeric biomaterials have been studied for GF delivery, including 
gelatin, alginate, ethylene-vinyl acetate, polyglycolic acid, PEG, chitosan, dextran, 
and different GAGs.7 However, many of these materials have no or limited sites for 
biologically specific molecular interaction with the GFs or for specific signalling 
interactions with cells of the target tissue. Growth factor delivery is therefore either 
driven by diffusion or degradation and not always in tune with the healing process. 
The use of Hep for GF incorporation is however a very promising approach due to its 
high affinity for GFs.  The Hep-GF interaction avoids GF damage, maintains 
biological activity upon release and relies on chemical degradation for GF release.16  
 
Since the delivery of Hep through hydrogels is well known for meeting the demands 
of both controlled and local release, as well as the numerous advantages for tissue 
engineering applications stated before, these gels are ideal GF delivery vehicles. It 
combines a synthetic component (PEG) to modulate bulk properties, such as 
modulus, biodegradability, crosslinking, and an ECM component (Hep) to sequester, 
stabilize and protect GFs. Simultaneously the gel serves as provisional ingrowth 
matrix to guide cell migration and regenerate functional tissue in the place of the 
hydrogels.  This conjugation does not only bring the GF into solution but also 
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increases the persistence of GF at the disease site, confining its availability to a 
targeted region and thus avoiding angiogenesis at unwanted sites.35 The presence of 
Hep is crucial since PEG hydrogels are normally resistant to cell adhesion, while 
evidence exists that Hep can promote cell adhesion.12,16,69,72,125,126 Functionalization 
with Hep further enables the gels to actively and selectively stimulate desired cell 
functions and maintain the functionality of the embedded GF during bulk material 
fabrication and release.62 Since the rate of Hep hydrogel degradation can be tailored 
by varying the extent of crosslinking and the breakdown products have active, pro-
angiogenic properties, the hydrogels actively participate in the tissue response, 
rather than merely serving as passive delivery mechanisms.112  
 
1.4 Heparinoid/PEG Hydrogels  
 
In order to ensure the controlled release and prolonged in vivo residence time of 
Hep/HS modification different approaches have been reported to covalently 
incorporate Hep/HS into hydrogels.  These methods include modification of free 
amine groups,52,127 carboxylic acid groups7–9,23,35,59,97 or hydroxyl groups12,69,128 on the 
polysaccharide.  Literature regarding the functionalization and crosslinking of GAGs, 
specifically Hep and HA, which can be copolymerized/crosslinked with PEG to form 
hydrogels suitable for controlled GF delivery, have been investigated, as discussed 
below and summarized in Table 2. Together, these works demonstrate the utility of 
covalently incorporating Hep into PEG-based hydrogels to promote cell adhesion, 
proliferation, differentiation and the controlled delivery of GFs for clinical applications 
in tissue regeneration.129  
 
1.4.1 Hyaluronic Acid: Hydroxyl Group Modification  
 
Smeds et al. methacrylated HA (HA-MA) by targeting the hydroxyl groups of HA with 
methacrylic anhydride (MAAn), whereafter they crosslinked it through photo-
polymerization with N-vinyl-2-pyrrolidone (NVP), 2,2-dimethoxy-2-
phenylacetophenone (DMPA) and ultraviolet radiation.73  Modification of HA 
hydroxyls was also performed in various other studies by making use of acrylic 
acid/acryloyl chloride/methacryloyl chloride, with or without the presence of phase 
transfer catalysts.  Thereafter these precursors were capable of hydrogel formation 
through enzyme mediated crosslinking.128,130 
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1.4.2 Hyaluronic Acid: Carboxyl Group Modification 
 
Peattie et al. functionalized the HA carboxyls with adipic dihydrazide (ADH), after 
activation with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and 
crosslinked it with PEG-dialdehyde. These hydrogels were capable of sequestering 
and releasing VEGF or bFGF, which successfully promoted a controlled angiogenic 
response in vivo.83,112 In another study dual GF-induced angiogenesis was obtained 
in vivo by preloading hydrogels with VEGF and keratinocyte GF (KGF).111 Hyaluronic 
acid was thiolated (HA-SH) by a reaction with 3,3-dithiobis(propionic hydrazide) 
(DTP), in the presence of the EDC, followed by reduction with dithiothreitol (DTT).  
Thereafter the HA-SH was crosslinked with acrylated PEG (PEG-Ac) through Michael 
type addition.111,131,132 Hahn et al. developed hydrogels capable of the sustained 
release of erythropoietin (EPO) by reacting the carboxylic acid groups of HA 
(activated by EDC) with ADH, followed by either MAAn or traut’s reagent to obtain 
methacrylated HA (HA-MA)96 or HA-SH,98 respectively.  Thereafter the HA-MA was 
crosslinked with DTT by Michael-type addition, and HA-SH with sodium tetrathionate. 
 
1.4.3 Heparin: Hydroxyl Group Modification 
 
Polyethylene glycol (PEG) hydrogels functionalized with Hep were utilized by Benoit 
et al. as a 3D synthetic scaffold for osteogenic differentiation of human mesenchymal 
stem cells (hMSCs): Hep-MA, formed by reacting MAAn with Hep, whereafter it was 
crosslinked by photo-induced polymerization with methacrylated PEG (PEG-MA) and 
analysed as a localized delivery vehicle for bFGF to promote cell adhesion and 
proliferation.12,16 A study performed by Nilasaroya et al. also made use of Hep-MA 
(Hep hydroxyl groups functionalized with glycidyl methacrylate, GMA), but 
crosslinked it with methacrylated polyvinyl alcohol (PVA-MA) through UV 
irradiation.69,133  Yamaguchi et al. also synthesised hydrogels capable of binding and 
releasing bFGF in a controlled manner, but through Michael-type addition of 
maleimide (Mal) functionalized Hep (Hep-Mal) with end-terminated star PEG.52 In this 
study the amine groups on Hep were N-deacetylated with hydrazine and reacted with 
succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate to obtain Hep-Mal, 
which was crosslinked with thiolated PEG (PEG-SH) and copolymerized with 
heparin-binding peptides (HIP) attached to vinyl sulfone functionalized PEG.52,127  
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1.4.4 Heparin: Carboxyl Group Modification  
 
Several researchers investigated the modification of the carboxylic groups on Hep. 
Recently Oliviero et al. developed hydrogels to elicit new micro-vessel growth in vivo 
through the sustained delivery of VEGF. Heparin was methacrylated, using N-(3-
aminopropyl) methacrylamide hydrochloride (APMMA), and crosslinked with PEG-
MA via photo-induced radical copolymerization.134 Similar to the approach of Peattie 
et al., Cai and co-workers thiolated Hep, HA and CS (Hep-SH, HA-SH and CS-SH, 
respectively) and covalently linked them, separately, to 20PEG8Ac via Michael-type 
addition reactions. These GAG-based hydrogels were investigated to stimulate in 
vivo angiogenesis through the slow release of non-covalently incorporated bFGF.7 
Similar hydrogels were synthesized and evaluated by Pike et al. and Elia et al., but 
for the controlled release of VEGF8 and combinations of the cytokine GFs (VEGF, 
angiopoietin-1, Ang-1, KGF and platelet-derived GF, PDGF),9 respectively. Both 
showed improved localized angiogenic responses to implanted Hep hydrogels in 
vivo.  
 
Vascular endothelial GF was non-covalently incorporated into hydrogels developed 
by Tae et al., who crosslinked modified Hep (through carbodiimide chemistry) with 
the NHS ester of PEG-bis-butanoic acid (SBA-PEG-SBA).23  In another study GF-
loaded hydrogels were also formed by copolymerization of SBA-PEG-SBA with 
hydrazide-functionalized heparin (Hep-ADH), to promote cartilage formation and 
chondrogenesis through the controlled release of bone morphogenetic protein-2 
(BMP-2), transforming GF-β2 (TGF- β2) and insulin-like GF-1 (IGF-1).135  
 
Successful sequestering and controlled release of bFGF for different wound-healing 
and vascular therapies were also achieved in various studies by crosslinking Hep-
Mal with PEG-SH through Michael-type addition.35,136–138 These studies utilized 
chemical methods that permit controllable modification of Hep with aminoethyl 
maleimide groups (AEM) by  employing EDC and 1-hydroxybenzotriazole hydrate 
(HOBt) as catalysts.35 Cell responses and adhesiveness of the gels were also 
studied using human aortic adventitial fibroblasts.138 In another example of 
carboxylate modification, Hep was thiolated with DTT, using cysteamines and 
carbodiimide chemistry, whereafter it was crosslinked with PEG-Ac using Michael-
type addition to form hydrogels capable of cell encapsulation, proliferation and GF 
release.59,97,139–141 Kim et al. and Tae et al. successfully encapsulated primary rat 
hepatocytes142 and fibroblast cells,97 respectively, within these hydrogels and 
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dedifferentiated chondrocytes were used to show that these hydrogels are further 
capable of inducing cartilage regeneration.139 
 
1.4.5 Heparin: Amine Group Modification 
 
To date many researchers have also made use of amide coupling for crosslinking 
injectable PEG-based hydrogels.10,11,84,143–147 Freudenberg et al. developed hydrogels 
by copolymerizing thiolated Hep with amino end-functionalized star-PEG (PEG-
Amine), after modification of the Hep carboxylic acid groups with sulfo-NHS.10,11,84 
These gels had shown to be successful at binding and delivering several GFs, 
including bFGF, VEGF, epidermal GF (EGF), PDGF and hepatocyte GF (HGF),84,144 
as well as dual GF delivery10,11,146 to promote angiogenesis and cell proliferation. 
More recently Baumann et al. and Prokoph et al. also employed these gels for the 
localized release of stromal cell-derived factor-1α (SDF-1 α), to promote 
stem/progenitor cell recruitment.143,145  
 
1.5 Release kinetics 
 
Since drugs can be physically or chemically incorporated into hydrogels through 
various methods, attached drugs may be controlled by different mechanisms and 
released with different kinetics. The most commonly considered mechanisms for drug 
release are swelling, diffusion, degradation and the breaking of covalent bonds.  To 
significantly ascribe experimentally obtained release data to any of these 
mechanisms, mathematical models are used. However, to assign an elution profile 
there are multiple parameters to consider and since each model makes certain 
assumptions it is only suitable for systems that fit those criteria.148 
 
A commonly used model to describe diffusion controlled elution is the Higuchi 
equation, but is only valid for non-swelling and non-degrading thin films and is 
therefore not applicable to describe elution from hydrogels.149,150 Models that 
consider swelling and degradation include the Hixson-Crowell and Korsmeyer-
Peppas equations.151 If experimentally obtained release data fits to the latter equation 
it may also be possible to distinguish whether the drug elution is primary controlled 
by the diffusion, swelling or a combination of the two mechanisms. 152 These 
equations were developed to describe the elution of physically incorporated 
drugs.153,154 The release of chemically incorporated drugs is generally determined by 
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the degradation rate of the covalent linker. These links are commonly designed to 
degrade through hydrolysis, giving rise to unique zero or first order elution 
profiles.86,154–156 Release data can be compared to representative equations to 
determine whether the release rate is dependent (first order) or independent (zero 
order) on the drug concentration.153  
 
Only a limited number of the studies regarding Hep or HA containing PEG hydrogels 
discussed in Section 1.4 (summarized in Table 2), investigated release kinetics.  Luo 
et al. loaded hydrogel films with anti-bacterial and anti-inflammatory drugs and found 
that pilocarpine, hydrocortisone, prednisolone and cortisone followed rapid first order 
release kinetics (released approximately whole amount in 10 min), while slow first-
order release kinetics (1-24 hours) were observed for dexamethasone and 
prednisone.83  Hydrogels comprising PEG-SH and Hep-Mal by Balwin et al. degraded 
via hydrolysis and released Hep, which also followed first-order kinetics.136 In a study 
by Benoit et al. bFGF released from Hep-MA gels followed zero order release 
kinetics,16 and in other studies with Hep hydrogels the release of VEGF6  and BMP-
2140 also followed near linear sustained profiles. Since GFs are connected to Hep via 
electrostatic forces, the release profiles are however not due to covalent linkages. 
Although GF release from Hep hydrogels developed by Elia et al. occurred in part 
through diffusion and in part through gel breakdown, release models were not 
investigated in the study.9 
 
Other factors influencing the release kinetics have also been reported in these 
studies, but were however not modeled. Yamaguchi et al. found that bFGF delivery 
from hydrogels was primarily matrix erosion controlled,52,127 while release test from 
HA-MA hydrogels by Hahn et al. showed that the EPO release profile was dependent 
on the crosslinking reaction time and temperature.96 Nie et al. showed that both the 
polymer concentration and Hep:GF ratio affected the release of bFGF.35  Several of 
the other studies also included release experiments and found that covalently 
crosslinked Hep significantly retarded GF release from hydrogels, which therefore 
resulted in more controlled and sustained delivery.7,8,10,59,69,84,134,141,143,144  
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Table 2: Summary of literature decribing the functionalization and crosslinking/copolymerization of GAGs with PEG to form hydrogels  
Functional 
group 
Reactions summary Gelation 
Reaction 
Biomedical Aspects and Applications GF/drugs released 
HA-OH 
Smeds et 
al. 2001; 
Kumar et al. 
2009 
• HA + MAAn  HA-MA 
• HA-MA + initiator + UV  gel73  
Photo- 
polymerization73  
Sealing wounds & reconstructing soft tissues; 
sutureless surgery73 
- 
• HA + Acrylic acid HA-Ac 
• HA-Ac + initiator + enzyme  gel128,130 
Enzyme-
mediated130 
Potential cosmetic, biomedical & 
pharmaceutical applications128,130 
- 
HA-COOH 
Peattie et al 
2004; 
Peattie et 
al. 2006; 
Hahn et al. 
2006a; 
Hahn et al. 
2006b 
• HA + ADH + EDC  HA-ADH 
• HA-ADH + PEG-dialdehyde  gel83,112 
Hydrazide- 
aldehyde 
reaction83,112  
Stimulation of  localized, synergistic angiogenic 
response in vivo;112 sustained release of anti-
bacterial & anti-inflammatory drugs83 
VEGF/bFGF;112 
Dexamethasone, 
cortisone, ect83 
• HA + DTP + EDC + DTT  HA-SH  
• Hep-SH + PEG-Ac  gel111,131,132   
Michael-type 
addition111,131,132 
Dual GF-induced angiogenesis;111 supports cell 
proliferation & growth;132 wound healing & 
tissue repair131 
VEGF & KGF;111 
fibroblast131,132 
• HA + ADH + EDC + MAAn  HA-ADH-MA 
• HA-ADH-MA + DTT  gel83,96   
Michael-type 
addition83,96 
Sustained release of EPO for the treatment of 
patients with anemia83,96    
EPO83,96 
 
• HA + ADH + EDC + traut's reagent  HA-ADH-SH 
• HA-SH + tetrathionate   gel83,98  
Michael-type 
addition83,98 
Sustained release of EPO for the treatment of 
patients with anemia83,98   
EPO83,98 
Hep-OH  
Benoit et al. 
2007; 
Nilasaroya 
et al. 2008;  
• Hep + MAAn  Hep-MA  
• Hep-MA + PEG-MA + initiator + UV  gel12,16 
Photo-
polymerization12,16  
Promote adhesion, proliferation & osteogenic 
differentiation12,16 
bFGF & hMSCs12,16 
• Hep + GMA Hep-MA 
• Hep-MA + PVA-MA + initiator + UV  gel49,69,157–159 
Photo-
polymerization49,69
,157–159
  
Presenting & activating GFs to promote cell 
proliferation;69 development of salivary gland157–
159
 
bFGF;69 Salivary 
cells157–159 
Hep-NH2 
Yamaguchi 
et al. 2005 
• Hep + hydrazine-N-deacetylate + Mal-NHS ester  
Hep-Mal 
• Hep-Mal + PEG-SH + PEG-HIP  gel52,127  
Michael-type 
addition52,127 
Bind & permit controlled release of GFs on the 
basis of specific peptide-heparin 
interactions52,127 
bFGF52 
 
Hep-COOH 
Oliviero et 
al. 2012; 
Cai et al. 
2005; Tae 
et al.2006; 
Nie et al. 
2007;Tae et 
al.2007; 
Fredenberg 
2009;  
• Hep + APMMA + EDC + HOBt  Hep-MA 
• Hep-MA + PEG-Ac + NVP + DMPA + UV  gel134  
Photo-
polymerization134  
Stimulation of in vivo angiogenesis134 VEGF 134  
• Hep + DTP + EDC + DTT  Hep-SH 
• Hep-SH + HA-SH + PEG-Ac  hydrogel7–9 
Michael-type 
addition7–9 
Stimulation of in vivo angiogenesis;7–9 dual GF-
loaded9 
bFGF;7 bFGF/VEGF;8 
VEGF, KGF&PDGF9 
• Hep + ADH + EDC + HOBt → Hep-ADH  
• Hep-ADH + SBA-PEG-SBA → gel23,135 
Hydrazide-NHS 
ester reaction23,135   
Stimulation of in vivo angiogenesis;23 promote 
cartilage formation & chondrogenesis, dual GF-
loaded135  
VEGF;23 IGF-1, TGF-
β2 & BMP-2135 
• Hep + AEM + EDC + HOBt/NHS  Hep-Mal 
• Hep-Mal
 
+ PEG-SH  gel35,136–138 
Michael-type 
addition35,136–138   
Sustained & controlled release of GFs;35,136–138 
improved cell adhesiveness138 
bFGF;35 bFGF, 
fibronectin138 
• Hep + Cysteamine + EDC + HOBt  Hep-SH 
• Hep-SH + PEG-Ac  gel59,97,139–141  
Michael-type 
addition59,97,139–141 
Improved cell proliferation;97 encapsulation & 
cultivation of primary hepatocytes;59 regenerate 
cartilage in partial-thickness defects139 
Fibrinogen;97 HGF;59 
BMP-2;140 TGF-β2139 
• Hep + EDC + sulfo-NHS  Hep-SH 
• Hep-SH + PEG-Amine  gel10,11,84,143–147  
Amide 
coupling10,11,84,143–
147
  
Neuronal differentiation & axo-dendritic 
outgrowth;84 cell recruitment;143,145 stimulation 
of in vivo angiogenesis;10,11 cell proliferation144   
bFGF;84 SDF-1α;143,145 
bFGF& VEGF;10,11 
EGF/bFGF;144PDGF146 
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1.6 Anti-inflammatory Effects of Heparin 
 
Although the anti-inflammatory properties of Hep are not the focus of this project it is 
important to understand the effects of Hep on the inflammatory response since the bulk 
fabrication of the gels, the chemical modification of the Hep and/or the presence of the 
GFs, among other factors, may interfere with the Hep and alter its properties. Since the 
hydrogels in this project (especially the degradable gels) are inert and formed in situ they 
are not expected to elicit a long-term inflammatory response. The gels are however in 
close contact with surrounding cells and therefore the anti-inflammatory properties of 
Hep should not be reduced during modification, incorporation or release.68  The use of 
Hep as anti-inflammatory agent has previously been hindered because these activities 
were only expressed at high Hep concentrations, where the anticoagulant effects 
predominate.2,160 Therefore HS hydrogels will also be developed for applications where 
strong anticoagulation is not desired.  
 
An inflammatory response is usually characterized by the recruitment and activation of 
leucocytes, which account for destruction of foreign pathogens and remodelling of 
inflamed tissues.161–164 Although leukocyte adhesion and activation are important 
components in wound healing, excessive adherence to the vascular endothelium may 
lead to intravascular aggregation and the release of undesirable oxygen radicals and 
proteolytic enzymes, which contribute to vascular and tissue damage. Inflammation is 
triggered and sustained by pro-inflammatory cytokines, prostaglandins and gaseous 
radicals.164–166 Pro-inflammatory mediators and enzymes can, once stabilized by their 
receptors, activate a range of inflammatory cells responsible to direct and promote 
leukocyte migration and activation167,168 and therefore most anti-inflammatory drugs 
target their production.2,169 
 
However, due to the high negative charge of Hep/HS, it is also known to moderate 
inflammation by binding and neutralising many different positively charged proteins 
involved in the inflammatory cascade.170 Heparin, therefore, either prevents the 
mediators and enzymes to interact with their respective receptors (inhibiting the 
activation of the inflammatory cells)171–174 or inhibits the actions of enzymes and cytotoxic 
mediators released from these activated cells.175–178 Other anti-inflammatory 
mechanisms of Hep/HS include its ability to inhibit adhesion of leukocytes (especially 
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neutrophils) to endothelial cells, as well as to limit their accumulation in inflamed 
tissues.3,170,172,179–182 On a molecular level Hep/HS has also shown to bind nuclear factor 
kappa B, a transcription factor responsible for the regulation of a series of cytokine and 
adhesion molecules.183,184   
 
When taking the different mechanisms responsible for the favourable anti-inflammatory 
properties of Hep/HS into account  and since there is at present no evidence of a 
specific sequence of the Hep chain needed to exert an anti-inflammatory response 
(unlike its antithrombotic properties), these properties are not expected to be influenced 
significantly during Hep/HS modification and hydrogel formation.2,3 
 
1.7 Cardiovascular Applications 
 
As this work forms part and contributes to a large research project concerning vascular 
grafts and myocardial infarction (MI) treatment a short section on cardiovascular disease 
(CVD) is given for additional context. 
 
Cardiovascular disease is a term used for a number of pathologies concerning the heart, 
its vascular network and the general vascular system throughout the body. Research 
conducted by Steyn and Fourie (2007) has shown that it is the second-biggest killer in 
South Africa by stating that, between 1997 and 2004, 195 people died per day due to 
CVD.185 It is however not just a problem in South Africa, but exists in all populations of 
the world, remaining the leading global cause of death.186,187 In a report from the 
American Heart Association it has been indicated that CVD accounts for 17.3 million 
deaths per year, representing 30% of all global deaths, and that this number is expected 
to grow to more than 23.6 million by 2030.13 Since more than half the deaths caused by 
CVD are premature (80% of deaths caused by CVD in 2008 occurred before the age of 
65 years), it not only has a major impact on people’s lives, but also on the workforce, the 
economy and a country as a whole.13,185–187 
 
Cardiovascular disease is often referred to as a “medical hydra” with no easy solution.188  
The first line of treatment is through non-pharmacological management - decreasing risk 
factors such as an unhealthy diet, use of tobacco, lack of exercise, stress, obesity, 
hypertension, diabetes, as well as high blood cholesterol.185 As the condition progresses, 
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more advanced treatment options for CVD are needed. Therapeutic approaches for CVD 
are multiple and include pharmacological therapy, mechanical devices and surgical 
interventions.189 However, most of the drugs used during these treatments (angiotensin 
enzyme inhibitors, beta-blockers, digoxin, diuretics, blood vessel dilators and calcium 
channel blockers, among others) have adverse effects, including worsening renal 
function, hyperkalaemia, hypotension, bradycardia and pericarditis.190 Surgical 
interventions currently used include bypass surgery, pacemakers, ultrafiltration, 
cardioverter defibrillators, heart valve surgery, infarct exclusion surgery, as well as heart 
transplantation.189,190 Although these methods are often successful, there are high risks 
and financial implications associated with them.189 
 
Despite the treatments currently available there is still an urgent need for improved 
therapeutics for CVD, especially to avoid progression of the disease which leads to the 
need of heart transplantation or invasive surgery. This project is therefore aimed at the 
synthesis, optimisation and use of degradable and non-degradable Hep and HS 
containing PEG hydrogels for the tissue regenerative treatment of CVDs, in general, and 
in vascular graft applications and MI treatment, in particular.  These hydrogels will be 
utilized in collaborative projects to facilitate spontaneous transmural endothelialisation in 
vascular grafts, by making use of the proven anticoagulative and angiogenic GF binding 
ability of Hep, while the latter ability will be employed in the treatment of MI though HS 
hydrogels.   
 
1.7.1 Vascular Graft Application 
 
Atherosclerosis is the slow, systemic build-up of plaque (fatty deposits, inflammatory 
cells and scar tissue) within the walls of arteries, which leads to compaction and loss of 
elastic tissue, calcification, ulceration, mural thrombosis, slow wall lysis, and 
consequently the cause of nearly three quarters of all CVDs.191 At present the most 
effective method to treat atherosclerosis is by surgical intervention during which the 
afflicted arteries are replaced or bypassed with vascular grafts.191,192 These grafts are 
therefore used for the treatment of numerous CVDs, such as ischemia, coronary heart 
disease and peripheral artery disease among others, through abdominal/thoracic aortic 
replacement or aortocoronary/pheripheral bypass surgery.192  
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Vascular grafts can be classified into two groups, namely bioprosthetic and synthetic 
grafts. Bioprosthetic grafts include autologous, homologous or heterologous tissues 
used in their untreated or modified form during bypass grafting procedures. However, 
due to the limited availability of healthy autologous vessels, grafts made either 
predominantly or completely of synthetic material are used as substitutes in vascular 
engineering. Since implantation of synthetic grafts often elicits a sequence of events, 
including acute and chronic inflammation, foreign body response, formation of 
granulation tissue, as well as fibrosis and fibrous encapsulation,193 long-term patency 
can only be achieved if these grafts are developed to be biocompatible. Synthetic grafts 
made of polymeric biomaterials are often favoured in tissue engineering applications, as 
long as they allow complete integration or silent acceptance within the body. Pennel et 
al. showed that synthetic vascular grafts with increased porosity and pore-size allow for 
transmural endothelialisation which allows tissue to populate the outer and inner surface 
of the graft, without resulting in increased intimal hyperplasia.194,195    
 
To further ensure graft patency the biocompatibility of these grafts can be improved by 
making use of hydrogels.  Injection of these gels into the pores of a vascular graft will 
improve constructive interaction between the graft and the host tissue, causing 
functional incorporation and healing.84,192,196  The use of degradable Hep hydrogels in 
vascular graft applications is based on several reasons: slow released Hep will decrease 
the thrombogenicity of the material, inhibit thrombogenesis inside the graft and attenuate 
inflammation. The PEG hydrogel, on the other hand, will ensure interaction with the host 
tissue by mimicking the ECM, serve as an ingrowth matrix to increase proliferation and 
migration of desired cell types into the material and minimize the long-term inflammatory 
response by degrading at the ingrowth rate.197 Moreover, the release of pro-angiogenic 
GFs will improve cell proliferation, angiogenesis and endothelialisation in the graft as 
well as in surrounding tissue, ensuring adequate and rapid vascularization to achieve 
tissue regeneration.8,9,110  
 
1.7.2 Myocardial Infarction Treatment  
 
The most common cause of heart failure is a CVD known as MI. In 2005, 8.1 million 
patients suffered an MI, while approximately one third of these patients developed heart 
failure.188 The heart responds to an MI by undergoing left ventricular remodelling,198,199 
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during which the left ventricle dilates to form a more spherical shape. This leads to an 
increase in left ventricular volume, elevated wall stress and, consequently, wall 
thinning.198,200,201 Although the initial remodelling may be compensatory for the damaged 
pump, by preserving stroke volume via the Starling mechanism, the increasing wall 
stress leads to further remodelling.198  This results in increasing interstitial fibrosis, 
cardiomyocyte hypertrophy, infarct expansion and/or further eccentric ventricular 
enlargement, which finally provokes heart failure.202,203  Although heart transplantation 
remains the “gold standard treatment” for heart failure, the need for donor hearts far 
exceeds their availability and therefore an urgent need for alternative therapies, which 
can prevent the progression of the disease to the extent that a transplantation is needed, 
exists.203 
 
The injection of hydrogels within the ventricular wall has been shown to be successful at 
increasing wall/scar thickness in the infarct zone,204–206 counteracting elevated wall 
stress within the infarcted heart,207 decreasing the infarct size,205 and reducing 
unfavourable left ventricular remodelling.206,208 Dobner et al. showed that the injection of 
a synthetic non-degradable PEG hydrogel as a permanent tissue integrated scaffold in a 
rat infarction model reduced left ventricular dilation post-infarct.80 However, due to its 
non-degradability the PEG gel caused an on-going foreign body response.203  The need 
for fully or partially degradable hydrogels, engineered to break down over several 
months, exists in order to potentially overcome the macrophage based inflammatory 
response, while still providing mechanical support for an extended period.  
 
Since heart failure is a very complex pathology, it is desirable that injected hydrogels 
have additional functionalities above that of stress relief. Although Hep has previously 
shown to  inhibit smooth muscle cell proliferation, moderate inflammation and control 
angiogenesis by potentiation of GFs,5,6 these activities were only expressed at high Hep 
concentrations, where the anticoagulant effects predominate.2,160 Bleeding side effects 
are therefore often associated with its use in some cardiovascular implementations, 
particularly in the left ventricle of the heart.14,203 Heparan sulfate hydrogels can however 
be developed to provide mechanical strength for the critical early stages of the infarct 
(where strong anticoagulation is not desired), while locally delivering pro-angiogenic GFs 
which will reduce left ventricular remodelling by increased angiogenesis.209–212  
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1.8 Aims and Strategies 
1.8.1 Aims 
 
The objective of the study was to design, synthesise, optimise and evaluate injectable 
degradable and non-degradable Hep and HS containing PEG hydrogels capable of 
controlled, localized GF delivery for improved angiogenesis in tissue regeneration 
applications. This will be achieved by: 
 
1. Modifying Hep and HS by covalent attachment of α,β-unsaturated groups, using 
controlled nucleophilic acyl substitution chemistry to achieve controlled and 
repeatable degrees of modification. 
2. Preparing hydrogels from the modified Hep/HS by Michael-type addition 
reactions with multithiol crosslinkers, either directly (to compare Hep versus HS 
effect) or by copolymerization with functionalized PEGs (to include 
degradability/non-degradability and control over the Hep/HS content). 
3. Retaining desired gel properties (crosslink density, degradation, stiffness and 
mesh size) when adding Hep/HS, while achieving controlled, extended and 
localized release of Hep/HS from the hydrogels.  
4. Controlling the anticoagulative properties of the gels and their eluates from highly 
to reduced anticoagulation by the use of Hep and HS, respectively, while 
retaining GF binding capability and anti-inflammatory properties. 
5. Binding pro-angiogenic GFs to the Hep/HS hydrogels and achieving controlled, 
extended and localized release of active GFs in vitro.  
6. Evaluating and achieving improved vascularization in vivo when Hep/HS 
hydrogels containing GF are used in regenerative scaffolds.  
 
1.8.2 Novelty of Project 
 
The novelties in this thesis include the development of a controlled and repeatable 
approach for the functionalization of Hep/HS hydroxyl groups using acrylate moieties, 
with optimal degrees of modification. This guaranteed gelation through spontaneous 
Michael-type addition with multithiols at physiological pH and temperature (pH = 7.4 and 
37 °C) in the absence of initiators or free radical polymerization, while retaining its 
activity and GF binding/delivery abilities. Since the specific Hep/HS modification method 
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does not produce leaving groups or spacers, Hep/HS is rendered in its original, 
unmodified form upon degradation of the relatively labile β-thio-ether ester linkages 
through hydrolysis.   
 
Limited studies regarding the modification, crosslinking, polymerization and the 
evaluation of rheological, swelling and anticoagulant properties of HS hydrogels; 
comparison with Hep gels; as well as the modelling of the controlled, slow release 
mechanism of Hep/HS from PEG hydrogels have been performed.  This work is 
therefore valuable to expand the understanding of the in vitro properties of these gels.  
 
Determination of retained antithrombotic activities of eluates from Hep/HS containing 
PEG gels through rotational thromboelastometry (ROTEM) and its comparison with 
thromboelastography (TEG) results are novel, as well as the incorporation of pro-
angiogenic GFs into these gels evaluated in vitro using enzyme-linked immunosorbent 
assay (ELISA).  The evaluation of these specific degradable, Hep containing hydrogels 
in vivo in a rat subcutaneous model using scaffolds provides valuable information for 
future implementation in certain cardiovascular regenerative applications,   specifically 
vascular grafts and myocardial infarct therapy.  
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2 Materials and Methods  
2.1 Materials 
 
All reagents were obtained from Sigma-Aldrich (Pty) Ltd. (Johannesburg, RSA), Fluka 
(Buchs, Switzerland) and Merck Millipore (Midrand, RSA), unless otherwise specified. 
Heparin (Hep) and heparan sulfate (HS) (both sodium salt, from porcine intestinal 
mucosa) were purchased from Celsus Laboratories (Cincinnati, Ohio, USA), while 8 
armed polyethylene glycol (PEG) with a molecular weight of 20 kDa (20PEG8OH) and 4 
armed PEG thiol (SH) with a molecular weight of 10 kDa (10PEG4SH) were obtained 
from Nektar Therapeutics, Huntsville, USA and Creative PEGworks, Winston Salem, 
USA, respectively.   
 
2.2 Nuclear Magnetic Resonance Spectroscopy  
 
1D (one-dimensional: 1H and 13C) and 2D (two-dimensional: Correlation Spectroscopy, 
COSY; Heteronuclear Single Quantum Coherence, HSQC; Total Correlation 
Spectroscopy, TOCSY; and Heteronuclear Multiple Bond Correlation, HMBC) Nuclear 
Magnetic Resonance (NMR) spectra were recorded using a Bruker DRX-400 
spectrometer under standard quantitative conditions (RT, 10 s recycle delay, 128 scans). 
The 2HOH signal (peak at 4.79 ppm) in proton experiments was suppressed by pre-
saturation for 3 s. All samples were dissolved at 4 mg/mL in CDCl3 and D2O (as 
indicated) and filtered (0.45 µm) prior analysis. MestreNova 10.0 software was used for 
phase correction, baseline subtraction and integration.   
 
2.3 Derivatization of Multi-arm PEG copolymers 
 
Branched 20PEG8OH was derivatized with either acrylate (Ac) or vinyl sulfone (VS) to 
form 20PEG8Ac (I) or 20PEG8VS (II), respectively by following protocols adapted from 
literature as briefly described below.47,80,213  
 
Synthesis of 20PEG8Ac: 20PEG8OH (10 g) was dissolved in 100 mL toluene.  The 
solution was dried by azeotropic distillation (110 °C, 1 hr, Ar flow 1 L/min), cooled to 30 
°C and diluted with dichloromethane (DCM, 37.5 mL). After further cooling (< 4 °C), 
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Triethylamine (TEA, 0.836 mL, 50 mole eq of OH groups) was added to the reaction 
solution, followed by the addition of acryloyl chloride (AcCl, 0.487 mL, 50 mole eq of OH 
groups) over 5 min. The reaction proceeded with stirring in the dark (overnight, RT).  
Purification was performed by filtration (to remove TEA/HCl salt), precipitation in diethyl 
ether (0 °C, 10 x excess volumes) and vacuum drying (RT, 750 mmHg, overnight). Re-
precipitation was performed twice from DCM (2-3 mL DCM/g) in diethyl ether (0 °C, 10 x 
excess volume). The product was re-dissolved in 5 mL deionized water (DI), dialyzed 
(cut off value = 1 kDa, 24h) against DI and freeze dried to obtain a slightly off white 
powder (66% yield, 93% acrylation, see Fig. 4).  
 
 
Figure 4: Structure of 20PEG8Ac (I, n≈54) 1H NMR (400 MHz, CDCl3): δ = 3.39-3.67 (m; 
PEG), 4.30 (t, J = 5.5 Hz; PEG-OCH2CH2Ac), 5.82 (dd, J = 10.4, 1.5 Hz; Hcis), 6.14 (dd, J = 
17.3, 10.4 Hz; Hgem) and 6.41 (dd, J = 17.3, 1.5 Hz; Htrans) ppm 
 
Synthesis of 20PEG8VS: 20PEG8OH (10 g) was dissolved in 100 mL DCM. The 
solution was dried on 4 nm molecular sieves (overnight, RT) and purged (Ar flow 2 
L/min).  Thereafter anhydrous DCM (400 mL) was added with subsequent addition of 
sodium hydride (NaH, 65% in oil, 0.74 g, 5 mole eq of OH groups) and additional DCM 
(100 mL). After divinyl sulfone (DVS, 20 mL, 50 mole eq of OH groups) was added, the 
reaction solution was purged again (30 min, Ar flow 0.5 L/min) and left to react in the 
dark (48 hr, inert atmosphere). Glacial acetic acid (3.5 mL) was used to quench the 
remaining NaH.  The resulting solution was filtered to remove precipitated acetate salt 
and its volume was reduced (to 100 mL) by rotary evaporation at RT. The product was 
purified as with I (30% yield, 94% modification, see Fig. 5).  
 
Percentage modification for both copolymers was calculated from the integration of vinyl 
proton peaks of Ac or VS groups and proton peaks of the PEG repeat unit (OCH2CH2) 
for I or II, respectively (see Appendix B, Fig. 44 or Fig. 45).   
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Figure 5: Structure of 20PEG8VS (II, n≈54); 1H NMR (400 MHz, CDCl3): δ = 3.24 (t, J = 5.7 
Hz, PEG-OCH2CH2VS), 3.44-3.73 (m; PEG), 3.89 (t, J = 5.7 Hz, PEG-OCH2CH2VS), 6.07 (d, J = 
9.9 Hz, Hcis), 6.38 (d, J = 16.6 Hz, Htrans) and 6.80 (dd, J = 16.6, 9.9 Hz, Hgem) ppm 
 
2.4 Molecular Weight Analysis of Heparin/Heparan Sulfate  
 
Determination of the molecular weight (MW) of Hep/HS (III) is complex due to its 
structural heterogeneity.  An experiment performed by 20 participating labs used gel 
permeation chromatography (GPC) with a single broad standard calibrant to determine 
the MW of Hep (sodium salt, from porcine intestinal mucosa) from Celsus Laboratories 
and since the same Hep was used in this project a MW of 15900 g/mole was used.214–218 
A molecular weight of 15000 g/mole was used for HS, as indicated by the supplier. The 
average MW of a disaccharide unit (dimer) was determined by using the following 
information from literature: (i) The major repeating dimer in Hep (see Fig. 6) accounts for 
at least 70% of dimers,25,26 (ii) combination of dimers making up the unique 
hexasaccharide sequence (which contains the pentasaccharide binding site for AT III) 
occurs in 33% of the chains219–225 and (iii) 85% of the glucosamines in Hep are N-
sulfated. 221,226 
Figure 6: Hexasaccharide sequence, containing the pentasaccharide binding site for 
antithrombin (a); schematic for Hep/HS (b); abbreviated structure for Hep/HS (c) 
 
Since (IdoA-2S)-(GlcNSO3-6S) in the hexasaccharide already accounts for 70% of the 
dimers, it can be estimated that (IdoA)-(GlcNAc-6S or GlcNSO3-6S) and (GlcA)-
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(GlcNSO3-3,6S) accounts for the other 30%, of which only 15% can be N-sulfated.  The 
average MW of a Hep dimer was therefore calculated to be 550 g/mole using Eq. 1. 
 
MW		
  0.7MW	  0.3MW/ 	 0.7MW 	  0.15MW  
0.075MW 		  0.075MW, 		      Eq. 1 
 
Heparan sulfate is considered to be similar in structure to Hep, but is less sulfated than 
Hep and has more than 20% N-acetylated glucosamine residues (GlcNAc and GlcNAc-
6S).227,228 This is confirmed by the comparison of Hep and HS spectra in Fig. 7, where 
the major signals appear in both spectra although they differ slightly in intensity and thus 
monosaccharide concentration. The integration of the signal of the N-acetylmethyl group 
(2.05 ppm) is also significantly higher in the HS than Hep spectra, confirming higher N-
acetylation of HS glucosamines.  
 
Figure 7: 1H NMR spectra of Hep and HS 
 
Based on the assumption that the major dimer is still most abundant (70%), the average 
MW of a HS dimer was calculated to be 515 g/mole using Eq. 2. 
 
MW		
  0.7MW  0.3MW/ 	 0.7MW   	0.2MW/  
0.05MW 	  0.05MW, 	      Eq. 2  
 
2.5 Synthesis of (Meth)acrylated Heparin/Heparan Sulfate  
 
Three different electrophilically activated acrylating reagents, acryloyl chloride (AcCl, 1); 
methacrylic anhydride (MAAn, 2) and glycidyl methacrylate (GMA, 3), were investigated 
for the modification of Hep and HS hydroxyl groups. Acrylation percentage (Ac %) was 
calculated by integration of three acrylate peaks representing vinyl protons (Hcis, Hgem, 
and Htrans, δ = 6.08, 6.21-6.35 and 6.53 ppm, respectively, see Fig. 13 or Fig. 47 in Appx. 
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B) over six peaks representing anomeric protons (A1, I1 and I5, δ = 4.87-5.61 ppm, see 
Fig. 11 or Fig. 47 in Appx. B) of Hep/HS, which is represented by Eq. 3.69,97,128 
 
	%&	%  	 ((*+,-./0*1230*45/)((7809809:) 	x	100        Eq. 3 
 
While methacrylation percentage (MA %) by integration of two methacrylate peaks (Hcis 
and Htrans, δ = 5.7 and 6.1 ppm, respectively) over the Hep/HS anomeric protons (see 
Eq. 4).69  
 
<=	%  	 ((>?@ABC0>DEC)((=F0GF0GH) 	I	
J
K 	I	FLL         Eq. 4 
 
2.5.1 Synthesis of Acrylated Hep/HS using Acryloyl Chloride 
 
Syntheses using AcCl (see Fig. 8) were performed by: 1a) controlled addition of AcCl, 
1b) interfacial reactions, 1c) phase transfer catalysts inclusion, 1d) buffer utilization and 
1e) usage of alternative solvents. Some of these methods were adapted from 
literature.229,230 
 
1a:  Hep/HS was dissolved in DI (0.02 g/mL) and stirred for 30 min (0 °C, pH = 
9.5, 0.5 mL 0.1 M NaOH) to deprotonate the hydroxyl groups. Thereafter AcCl (2.5 mL, 
20 mole eq of OH groups, 2.5 mL/h) was added to the Hep/HS solution with a syringe 
pump, ensuring controlled addition.130 The reaction solution was allowed to stir for 
another hour (< 5 °C, pH = 8-9, 10 mL 1-5 M NaOH).  Purification was performed by 
filtration of the reaction solution, precipitation of the filtrate in ethanol (0 °C, 10 x excess 
volume) followed by centrifugation (5 min, 2000 rpm, 0 °C), and vacuum drying of the 
resulting precipitate (RT, 750 mmHg, overnight).  The product was re-dissolved in DI (5 
mL), dialyzed (cut off value = 1 kDa, 24 hr) against DI and freeze dried (61-94% yield, 
20-80%  
1b: Three different interfacial reactions were performed: (i) N-hexane (Hex, 10 
mL) was poured onto a Hep/HS solution (0.02 g/mL in DI) which had been stirred for 30 
min (0 °C, pH = 9.5). Once an interface stabilized, AcCl (2.5 mL, 20 mole eq of OH 
groups) was added over 30 min. The solution was stirred for another hour (< 5 °C, pH = 
8-9, 7 mL 1 M NaOH) whereafter the Hex was poured off and the resulting Hep/HS 
solution was purified, as with 1a (52% yield, 8% acrylation).  (ii) A similar procedure to (i) 
30 
 
was followed, but dichloromethane (DCM) was used instead of Hex (58% yield, 6% 
acrylation). (iii) A mixture of AcCl (2.5 mL, 20 mole eq of OH groups) and DCM (2.5 mL) 
was added to a Hep/HS solution (0.02 g/mL in DI) over an hour, stirred for another hour 
(< 5 °C, pH = 8-9, 1 M NaOH) and purified as with 1a (58% yield, 12% acrylation).    
1c: A solution of Hep/HS in DI (0.02 g/mL) was stirred for 30 min (0 °C, pH = 
9.5). AcCl (2.5 mL, 20 mole eq of OH groups), DCM (2.5 mL), 4-dimethylaminopyridine 
(DMAP, 0.07 g, 6.4 mole eq of OH groups) and tetra-n-butylammonium bromide (TBAB, 
0.08 g, 2.7 mole eq of OH groups) were mixed together and added to the Hep/HS 
solution over an hour.231–234  Thereafter the solution was stirred for another hour (< 5 °C, 
pH = 8-9, 1 M NaOH) and purified as with 1a (71% yield, 14% acrylation).  
1d: Hep/HS (0.5 g) was dissolved in a phosphate buffer (pH = 8, 0.5 M, 1.65 g 
Na2HPO4 and 0.1 g NaH2PO4 in 25 mL DI, 0 °C) and stirred for 30 min. AcCl (2.5 mL, 20 
mole eq of OH groups) was added to the Hep/HS solution over an hour, stirred for 
another hour (< 5 °C, pH = 8-9, 1 M NaOH) and purified as with 1a (45% yield, 1% 
acrylation). 
1e: Hep/HS (50 mg in 100 µL water) was dissolved in dimethyl sulfoxide (DMSO, 
25 mL, 12 °C, pH = 11.4), whereafter AcCl (250 µL, 500 µL or 1000 µL; 10, 20 or 40 
mole eq of OH groups) and triethylamine (TEA, 431 µL, 862 µL or 1724 µL; 1:1 ratio of 
AcCl) were added over an hour (8-12 °C, pH = 8-9). Purification was performed as with 
1a, but precipitation was performed using acetone instead of ethanol (56-63% yield, 0%, 
3% and 9% acrylation for 10, 20 or 40 mole eq, respectively). 
Figure 8: Reaction of Hep/HS (III) with AcCl to form Hep/HS-Ac (IV); 1H NMR (400 MHz, 
D2O): δ = 6.08 ppm (dd, J = 18.6, 9.0 Hz, Htrans), 6.21-6.35 (m, Hgem), 6.53 (d, J = 17.4 Hz, Hcis) 
ppm  
 
2.5.2 Synthesis of Methacrylated Hep/HS using Anhydride Chemistry 
 
Hep/HS (0.02 g/mL in DI, 4 °C) was reacted with MAAn (2.5 mL, 20 mole eq of OH 
groups) for 2, 5, 8 or 16 hours (pH = 8.5, 5 mL 1M NaOH) as in Fig. 9 and followed by 
thin layer chromatography (TLC; ether), as adapted from literature.12,16,73 Purification was 
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performed as with 1a, with an additional re-precipitation step from DI into ethanol (51-
60% yield, 11-13% acrylation). 
 
Figure 9: Reaction of Hep/HS (III) with MAAn to form Hep/HS-MA (V); 1H NMR (400 MHz, 
D2O): δ = 5.84 (d, J = 21.3 Hz, Htrans), 6.24 (d, J = 22.9 Hz, Hcis) ppm 
 
2.5.3 Synthesis of Methacrylated Hep/HS using Epoxy Chemistry 
 
Hep/HS (0.1 g/mL in PBS2, pH = 7.4, RT, see Appendix A for PBS2) was reacted (RT, 14 
days, Fig. 10) with GMA (127 µL, 318 µL or 636.5 µL; 2, 5 or 10 mole eq of OH groups) 
subjected to vigorous stirring.  The reaction was followed by TLC (toluene), as adapted 
from literature.49,69 Purification was performed as with 1a, but re-precipitation was 
performed from DI into acetone (44-61% yield, 11-19% acrylation). 
 
 
Figure 10: Reaction of Hep/HS (III) with GMA to form Hep/HS-MA (V) through 
transesterification or epoxy ring opening (3-methacryloyl-1-glyceryl ester, VIa, or 
methacryloyl-2-glyceryl ester, VIb). 1H NMR (400 MHz, D2O): δ = 5.83 (s, Htrans), 6.27 (s, Hcis) 
ppm 
 
2.6 Analysis of Heparin/Heparan Sulfate Hydroxyl Groups 
 
The number and position of Ac groups on modified Hep/HS were evaluated by 
performing a thorough study of the compositional analysis of Hep/HS using NMR. Based 
on the analysis of spectra COSY (Fig. 48 and 49, Appx. B), HSQC (Fig. 50 and 51, 
Appx. B), TOCSY (Fig. 52, Appx. B) and HMBC (Fig. 53, Appx. B) of Hep and HS, 
32 
 
assignments were made for the major signals in the 1H and 13C NMR spectra, as 
displayed in Fig. 11 and 12, respectively. The signals respond to the main constituent 
monosaccharide residues of Hep/HS and are assigned as follow: A1: H1 of GlcNSO3-6S 
linked to GlcA; A1: H1 of GlcNSO3-6S linked to IdoA-2S; A1: H1 of GlcNSO3 linked to 
IdoA-2S; I1: H1 of IdoA-2S; I1: H1 of IdoA; I5: H5 of IdoA-2S linked to GlcNSO3-6S; A6: 
H6a of GlcNSO3-6S; I2: H2 of IdoA-2S; A7: H6b of GlcNSO3-6S; I3: H3 of IdoA-2S; I4: H4 
of IdoA-2S; A5: H5 of GlcNSO3-6S; A4: H4 of GlcNSO3-6S; A3: H3 of GlcNSO3-6S; A2: H2 
of GlcNSO3-6S; A2: H2 of GlcNAc; Ac: N-acetylmethyl protons. The positions of the 
signals for the 13C NMR spectra are similar, but refer to the carbon instead of the proton 
(due to structure similarity only Hep spectra are further shown in this project; see Fig. 47 
in Appendix B for proof of structure similarities). 
 
  
Figure 11: 1H NMR spectrum of Hep with major signals  
 
 
Figure 12: 13C NMR spectrum of Hep with major signals  
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Since Hep and HS contain primary and secondary hydroxyl groups it was necessary to 
determine whether the primary and/or secondary hydroxyl groups were modified. 
Primary hydroxyls of most polysaccharide are less sterically hindered and more 
nucleophilic than secondary hydroxyl groups, therefore the reaction of acrylates with 
primary hydroxyls was expected to be faster in comparison to secondary hydroxyls.235,236 
The peak at 61 ppm (indicated by green arrow) in the Hep spectrum (Fig. 12) represents 
the methylene carbon (A6 and A7) of GlcNAc (see Fig. 46 in Appendix B for more 
detail).  This peak is absent in the Hep-Ac spectrum, showing that all free primary 
hydroxyl groups were modified. However, since the signal is very small it implies that a 
small concentration of free primary hydroxyl groups is present in Hep, as confirmed by 
Toida et al. who found that only 4.8% of Hep dimers contained a primary hydroxyl 
group.20,237  
 
After investigating acrylation percentages (reaching up to 80%) it was apparent that 
secondary hydroxyl groups were modified as well, since more modification occurred than 
primary hydroxyl groups present in Hep. Monosaccharide residues present in Hep were 
identified by using scalar connectivities in COSY (Fig. 48 and 49, Appendix B), but due 
to the structural complexity the peaks overlapped to a great extent. This resulted in 
similar coupling constants obtained for different Hep-Ac modification 
sites.238,239 However, HSQC of Hep-Ac in Fig. 13 clearly showed the correlation between 
vinyl proton (Htrans, Hgem, Hcis) and carbon peaks (Ca, Cc, Cb) at 6.53/133.4, 6.28/127.1 
and 6.08/133.4 (indicated in red box).  
 
Cross peaks also appeared at 5.4/70.1 and 4.5/73.4 (circled in green) after acrylation 
which suggest deshielding of the protons on carbons at A3 and I2. Deshielding these 
protons resulted in the shielding of neighbouring carbons, which caused their proton 
signals to shift to the anomeric region. This systematic deshielding effect of the ring 
carbon at the position of attachment is characteristic of acrylation reactions, among 
others,240,241 which suggest that the secondary hydroxyl attached to the carbon at A3 and 
I2 was acrylated.  TOCSY and HMBC of Hep-Ac were also investigated to determine the 
number and position of Ac groups, but could not provide additional information due to 
partial esterification and the heterogeneous structure of Hep causing resonance 
overlaps.   
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Differentiation between the nucleophilicity of the different secondary hydroxyl groups in a 
polysaccharide is often difficult and almost impossible in a heterogeneous structure such 
as Hep.236,242,243 It can therefore only be suggested that most modification occurred at 
the secondary hydroxyl attached to the carbon at A3 and I2 of the major dimer.240,241 It 
can further be suggested that more modification occurred on glucosamine (at A3) than 
uronic residues (at I2), since the steric space occupied by the carboxyl groups on the 
uronic residues restricts modification. If carbon-13 enriched AcCl is used, which has 
been targeted at position Ca trough neutron activation, the exact modification positions 
might be determined. This process is however very specialized, expensive and 
unnecessary regarding the scope of this study. 
 
 
Figure 13: HSQC spectrum of Hep-Ac, with 1H and 13C NMR of Hep and Hep-Ac for 
comparison. Acrylate proton (Htrans, Hgem, Hcis) and carbon peaks (Ca, Cc, Cb), as well as 
correlation indicated in red boxes, crosspeaks due to deshielding shown by green circles   
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After determination of the position of Ac groups, it is possible to calculate the number of 
Ac moieties per Hep/HS chain after modification. The number of dimers per chain was 
calculated as 29 for Hep and HS, using Eq. 5. 
 
Dimers	per	chain  XYZ2[/Z\XYZ2[/Z\	]532,	        Eq. 5 
 
Since primary and/or secondary hydroxyls were modified the major dimer has two 
possible modification sites (hydroxyl groups) and the rest of the dimers either have one, 
two or three.  A Hep chain therefore has approximately 58 hydroxyl groups (on average 
two per dimer). Thus, 40% acrylation represents approx. 11 Ac groups per Hep/HS 
chain, 10% acrylation represents approx. 3 Ac groups per Hep/HS chain, and 3% 
acrylation represents less than 1 acrylate group per Hep/HS chain. 
 
2.7 Gel Formation 
 
Two gel formation methods were investigated as briefly described below, i.e. photo-
polymerization and Michael-type addition reaction. Although both methods were used to 
test the viability of Hep/HS-Ac and Hep/HS-MA to form gels when reacted with PEG 
crosslinkers, photo polymerization was not further investigated after the determination of 
gel formation due to the many advantages Michael-type addition reactions hold over 
photo-polymerization for the proposed applications of this study.7,12,23,80,96  
 
2.7.1 Photo-polymerization 
 
Gels (100 µL, 10m% nominal Hep/HS-Ac concentration) were formed by mixing 10 mg 
of Hep/HS-MA (V) or Hep/HS-Ac (IV) in 50 µL PBS2 with 19.5 µL of 2,2-dimethoxy-2-
phenylacetophenone (DMPA; 4.7 mg in 5 mL NVP; 1 mole% DMPA and 1000 mole% 
NVP regarding Ac groups).  Thereafter it was irradiated by UV light (100 W, 5 min) at a 
distance of 15 cm.  Control gels were made by UV irradiation of modified Hep/HS, a 
mixture of modified Hep/HS and DMPA (1 mole%), a mixture of modified Hep/HS and 
NVP, as well as a solution of DMPA in NVP (0.94 mg/mL); all in 100 µL PBS2. 
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2.7.2 Michael-type addition reaction 
 
Two different gel formulation groups were investigated for gels formed through Michael-
type addition reactions and are referred to as Type 1 and 2 gels. Type 1 gels were 
formed by crosslinking 10% mass per volume Hep/HS-Ac with a stoichiometric amount 
of star-shaped PEG tetra thiol crosslinker (10PEG4SH, VII, see Fig. 14).  Since Hep has 
previously been incorporated into similar hydrogels by our group, as well as various 
authors,8,16,35,69,97,127 Type 1 gels were formed to compare the effect between Hep and 
HS in hydrogels. However, the large amount of Hep/HS present in these gels can be 
detrimental for the particular in vivo application and was therefore only tested in vitro.   
 
 
Figure 14: Structure of 10PEG4SH (VII, n≈54) used as crosslinker in Michael-type addition 
reaction 
 
Type 2 gels were formed by crosslinking 4% mass per volume copolymer with a 
stoichiometric amount of PEG crosslinker (10PEG4SH). The copolymers were either 
20PEG8Ac or 20PEG8VS (to form Type 2D and 2N gels, respectively) and Hep/HS-Ac 
(1.5 mass% of the copolymer). Type 2 gels provided more control over the Hep/HS 
content and the degradable nature of the gels - the reduction in solid content was based 
on faster ingrowth in vivo (as seen by Bracher et al.244) and the amount of Hep/HS-Ac 
was reduced based on the minimal Hep concentration capable of effective control of 
release,8 as well as the potential of this amount of Hep/HS in a 100 µL gel to cause 
anticoagulation in a rat model without causing excessive bleeding or adversely affecting 
mechanical properties of the gels.69 Since the effect of the covalent incorporation (CI) of 
Hep/HS into gels were investigated (in vitro and in vivo), control gels (without Hep/HS-
Ac) and non-covalently incorporated (NI) gels (with unmodified Hep/HS instead of 
Hep/HS-Ac) were also formed.   
 
The different gel formulations of Type 1 and 2 (D and N) gels are summarized in Table 3 
followed by a brief description of their formation methods. It is important to note that only 
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Hep and HS modified by 40% acrylation was used, because that functionality has been 
determined to be high enough to guarantee gelation through Michael-type addition 
(previously seen by our group), while taking Hep/HS activity and its ability to sequester 
and release GFs into account.35,69  
 
Table 3: Summary of the different gel formulations of Type 1 and 2 gels with their contents 
and abbreviations 
    Copolymers (%**)*** 
Categories Abbreviation Hep HS Hep-Ac HS-Ac PEG-Ac PEG-VS 
Ty
pe
 
1 
 Hep-Ac/SH  - - 10 - - - 
HS-Ac/SH - - - 10 - - 
Ty
pe
 
2 
 
Ty
pe
 
2D
 
 
Control PEG-Ac/SH - - - - 4 - 
NI gels PEG-Ac/SH/Hep  0.06* - - - 3.94 - 
PEG-Ac/SH/HS - 0.06 - - 3.94 - 
CI gels PEG-Ac/SH/Hep-Ac  - - 0.06 - 3.94 - 
PEG-Ac/SH/HS-Ac - - - 0.06 3.94 - 
Ty
pe
 
2N
 
 
Control PEG-VS/SH - - - - - 4 
NI gels PEG-VS/SH/Hep  0.06 - - - - 3.94 
PEG-VS/SH/HS - 0.06 - - - 3.94 
CI gels PEG-VS/SH/Hep-Ac  - - 0.06 - - 3.94 
PEG-VS/SH/HS-Ac - - - 0.06 - 3.94 
 
*1.5m% of 4m% copolymer; Type 2D: degradable gels; Type 2N: non-degradable gels **mass 
percentage of copolymer present in the gel; *** 1:1 mole ration of crosslinker (10PEG4SH) added 
in comparison to copolymer   
 
Type 1 gels: Gels were made (100 µL, n = 3, 10m% nominal Hep/HS-Ac concentration) 
by reacting Hep/HS-Ac (IV, 10 mg in 50 µL PBS2) with 10PEG4SH (VII, 17.9 mg in 50 µL 
PBS2) in a 1:1 mole ratio of SH to Ac groups (according to Eq. 6), and was allowed to 
react for 2 hr at 37 °C.   
 
^_*  ^7`  Ac	%	х	2	x cZ2[/Z\XYZ2[/Z\	]532,	         Eq. 6 
 
Where nSH is the mole of thiol groups, nAc is the mole Ac moieties, Ac % is the 
percentage acrylation, mHep/HS is the mass of Hep/HS and MWHep/HS dimer is the molecular 
38 
 
weight of a Hep/HS dimer. Type 1 gels are specifically referred to as Hep-Ac/SH and 
HS-Ac/SH throughout the thesis and the reaction is illustrated in Fig. 15. 
Figure 15: Reaction scheme of Type 1 gel formation through Michael-type addition 
reaction using Hep/HS-Ac and stoichiometrically equivalent amounts of 10PEG4SH 
crosslinker 
 
Type 2 gels: Covalently incorporated (CI) gels (100 µL, n = 4, 4m% nominal copolymer 
concentration) were made by reacting 0.06 mg of Hep/HS-Ac (IV, 1.5m% of 4m% 
copolymer) in 10 µL PBS2 with 10PEG4SH (VII, 4.04 mg in 50 µL PBS2), followed by the 
addition of 20PEG8Ac (I) or 20PEG8VS (II) (3.94 mg of in 40 µL PBS2) at 37 °C to form 
degradable (Type 2D) and non-degradable (Type 2N) gels, as illustrated in Fig. 16. The 
ratio of SH to total functional groups was 1:1, and determined using Eq. 7. 
 
Figure 16: Reaction scheme for the pegylation and copolymerization of Type 2 CI gels 
using Hep/HS-Ac, 20PEG8Ac or 20PEG8VS (degradable or non-degradable gels, 
respectively) and stoichiometrically equivalent amounts of 10PEG4SH crosslinker 
 
^_*  n9	de	99  Ac	%	х	2	x cZ2[/Z\XYZ2[/Z\	]532,		        Eq. 7 
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Where nI or II is the mole Ac or VS moieties.  Non-covalently incorporated (NI) gels (100 
µL, n = 4; 4m% nominal copolymer concentration) were made similarly to CI gels, but 
Hep/HS was used instead of Hep/HS-Ac. Control gels (100 µL, n = 4, 4m% nominal 
copolymer) were made by reacting 10PEG4SH (VII, 4 mg in 50 µL PBS2) with I or II (4 
mg in 50 µL PBS2) at 37 °C. In all cases the gels formed within 10 min, but were allowed 
to crosslink for 2 hr. The complete gel study design is represented in Table 4. 
 
Table 4: Schematic representation of gel study design  
Chemistry Type of gel, contents and abbreviations Analyses performed 
Photo-
Polymerization 
Hep/HS-MA or Hep/HS-Ac + initiator + UV  
 
Gel formation 
Michael-type 
Addition 
 
Ty
pe
 
1 Hep-Ac/SH  Gel formation, gelation times, 
viscoelasticity, swelling, Hep/HS 
elution and activity in vitro 
HS-Ac/SH 
Ty
pe
 
2 
Ty
pe
 
2D
 
Control PEG-Ac/SH* Gel formation, gelation times, 
viscoelasticity, swelling, mesh size, 
Hep/HS elution and activity, GF 
incorporation and release in vitro; * in 
vivo 
NI gels PEG-Ac/SH/Hep* 
PEG-Ac/SH/HS 
CI gels PEG-Ac/SH/Hep-Ac* 
PEG-Ac/SH/HS-Ac 
Ty
pe
 
2N
 
Control PEG-VS/SH Gel formation, gelation times, 
viscoelasticity, swelling, mesh size, 
Hep/HS elution and activity in vitro 
NI gels PEG-VS/SH/Hep  
PEG-VS/SH/HS 
CI gels PEG-VS/SH/Hep-Ac  
PEG-VS/SH/HS-Ac 
 
2.8 Porous Scaffold Production 
 
Porous polyurethane (PU) rods (5 mm OD) were produced via phase inversion/porogen 
extraction.110,245  Cylindrical columns of sized gelatin beads (125–180 µm, Thies 
Technologies, St Louis) were infiltrated with a 20% (m/m) solution of segmented PU 
(M48) in N-methylpyrrolidone (NMP, 4 hr, 1000 kPa). Resultant polymer/solvent/porogen 
rods were solidified and precipitated in ethanol (2 days in a rotating precipitation tube). 
Porogen extraction, extensive washing and drying resulted in porous scaffolds. Disks 
were uniformly sliced (2 mm thick) and sterilized in ethylene oxide, whereafter pore sizes 
were measured using scanning electron microscope (SEM) images (Image J software; n 
= 3). In Fig. 17, SEM images of PU disks revealed macro-pores and interconnecting 
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windows of 156.9 ± 1.2 µm and 76.4 ± 2.0 µm, respectively, with a porosity of 82.3 ± 
2.4%.  
 
 
Figure 17: SEM of pores and interconnecting windows (a), the hemi-cylindrical shape as 
cut during explantation (b) and the outside surface (c) of the PU disk at 500x, 75x and 200x 
magnification, respectively, before hydrogel infiltration and implantation  
 
2.9 Rheology 
 
An AR-1500 rheometer (TA Instruments Inc.) with 20 mm diameter standard steel 
parallel-plate geometry was used for the characterization of all samples. Oscillatory time, 
stress and frequency sweep tests were employed. Time sweep monitored the in situ 
gelation of gels (100 µL, n = 3) over 30 min (50 µm gap thickness) at constant strain 
(2%), temperature (25 °C) and frequency (1 Hz). Storage (G′) and loss moduli (G′′) were 
recorded over time. Gelation time was defined as the crossover between G’ and G’’, 
which is in compliance with the criteria of Chambon and Winter who found G’ and G’’ to 
be congruent over a wide range of frequencies at gel point and corresponds to a 
constant phase angle of 45°.68,246,247 
 
Gels (200 µL, n = 3, 22 mm diameter, 0.5 mm thick) used in stress and frequency sweep 
tests were formed between siliconized (Sigmacote) glass coverslips (2 hr, 37 °C). 
Formed gels were detached after gelation and individually immersed in PBS1 (see 
Appendix A) to swell to equilibrium (37 °C, overnight). To prevent slippage the plate 
height was adjusted, starting from the original sample height and compressing the 
sample to reach a normal force of 30% compression (0.75-1 mm gap thickness). Stress 
sweep (G’ as a function of oscillatory stress) was performed by shearing the gels (1-
2000 Pa) at constant frequency (1 Hz) and temperature (25 °C) until structure 
a b c 
41 
 
breakdown. This was done to determine the ranges in which G’ of swollen gels are 
constant when subjected to stress, which are regarded as the linear viscoelastic regions 
(LVR) of the gels and needed to evaluate the viscoelastic properties of different 
gels.248,249. Frequency sweep (G’ and G’’ as a function of oscillatory frequency) was 
performed at a constant shear stress (50% of the LVR) by varying frequency from 1 to 
100 Hz, to determine the mechanical stiffness of the gels.81,248   
 
2.10 Hydrogel Swelling 
 
Two swelling ratios were determined in this project, namely swelling ratio 1 (Q, ratio of 
swollen over dried gel volumes determined through volumetric procedures) and 2 (SR, 
ratio of swollen over wet gel masses determined through gravimetric procedures). 
Although hydrogel swelling is normally defined as Q, which accounts for the loss of 
polymer during swelling,64,81,133,250–252 SR mirrors the degree of swelling compared to the 
formed gel rather than to its dry content, which is an important parameter for in vivo 
applications.99 Additionally, weighing the same gels repeatedly (for SR), instead of 
sacrificing gels through drying (for Q), is an efficient way to economise a limited amount 
of material. Due to the high water content both ratios are accurate representations of 
swelling. As per Flory-Rehner theory mesh sizes were determined to predict whether 
cellular invasion into gels could be achieved while facilitating the delivery of Hep/HS and 
GFs in vivo.7,97,253 
 
2.10.1 Swelling ratio 1 (Q) using volumetric procedure 
 
The volumes of gels (n = 3) were determined according to Archimedes’ principle using a 
5-decimal balance equipped with a density determination kit (Mettler Toledo). Gels were 
weighed (directly after crosslinking or after individually immersed in 1 mL PBS1, pH = 
7.4, incubated at 37 °C) in air and DI, dried (50 °C, overnight) and then weighed in air 
and DI again. Volumes of the formed (Vg), swollen (Vs) and dried (Vd) gels were 
calculated from the respective mass according to Eq. 8.  
 
f  ghijgkGlmn     Eq. 8   o 
fpfq
fq     Eq. 9 
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Where V is volume of the gels, mair is mass of the gel weighed in air, mDI is mass of the 
gel weighed in DI and ρDI is the density of DI at RT.  Thereafter Eq. 9 was used to 
calculate Q for hydrogels.  
 
2.10.2 Swelling ratio 2 (SR) using gravimetric procedure 
 
Gels (n = 4) were weighed directly after crosslinking to determine formed gel mass (Wg) 
by using a 5-decimal balance (Mettler Toledo).  Thereafter the gels were individually 
immersed in PBS1 (1 mL, pH = 7.4) and placed in an incubator (37 °C) for swelling and 
Hep/HS elution. Gels were removed at regular intervals and weighed in their swollen 
state (Ws) to follow swelling and degradation as a ratio of Ws/Wg over time. The eluates 
were collected and replaced by fresh PBS1 at predetermined time points. The end points 
of Type 2D gels were considered to be reached when eluates could no longer be 
replaced without damaging the gels, which were substantially weakened by degradation. 
Since previous experiments in our laboratory for non-degradable gels similar to Type 2N 
gels did not show degradation while incubated for more than a year (not shown), these 
gels were measured until all the Hep/HS had theoretically been released, as determined 
through Hep/HS eluting experiments.  
 
2.10.3 Mesh Size Calculations 
 
The average molecular weight between crosslinks (Mc) in the gel network was calculated 
using Eq. 10,254 with the molecular weight of the PEG building block (Mn = 20 kDa), the 
specific volume of the PEG building block before crosslinking (ū = 0.861 mL/g), the 
molar volume of water (V1 = 18.1 mL/mole) and the polymer-solvent interaction 
parameter for a PEG-water system (χ = 0.426) used as constants. 
 
F
rs 	
K
rt −	
( vwfF)xytzFvK,p{0	vK,p0	|vK,p
K}
vK,j~ vK,pvK,j
J FK(
vK,p
vK,j)
        Eq. 10 
 
Experimental data is represented by u2,s and u2,r (as calculated by Eq. 11 and Eq. 12, 
respectively) using volumes of dried (Vd), swollen (Vs) and formed (Vg) gels.  
 
vK,p 	 C                           Eq. 11                  vK,j 	

   Eq. 12 
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Thereafter Flory-Rehner calculations were used to calculate the average mesh size, ζ 
(Å), for the gels during degradation over time, (Eq. 13) with the characteristic ratio of 
PEG (Cn = 4) and the bond length of the gel’s polymeric backbone (l = 1.48 Å) as 
contants. 
 
  pyt           Eq. 13 
 
Experimental data (αs) is represented by Eq. 14 and the number of bonds between two 
crosslinks (N) was calculated according to Eq. 15 using the molecular weight of the PEG 
repeat unit (Mr = 44 g/mole).  
	
p 	 FvK,pJ                            Eq. 14                    	
Jrs
rj    Eq. 15 
 
Since system specific constants for gels made predominantly from Hep/HS-Ac (i.e. Type 
1 gels) were not available, average mesh size calculations were only performed for Type 
2 gels. These gels were assumed to be similar to unmodified PEG gels, as the gels 
contained only a small amount of Hep/HS (1.5% of 4m% copolymer).  
 
2.11 Heparin and Heparan Sulfate Elution 
 
The eluates (n = 4), collected at different time points, were used to quantitatively 
determine Hep/HS elution over time by using a calorimetric method known as an MBTH 
(3-methyl-2-benzothiazoline hydrazone-hydrochloride) assay, adapted from literature.255  
Each eluate (250 µL) was reacted with a nitrous acid solution (500 µL, 0.025 M HNO2, 1 
M HCl) for 30 min (sonicate, RT) to cleave and deaminate N-sulfated glucosamine 
residues. Degradation was stopped by the addition of a 1 M ammonium sulfamate 
solution (250 µL).  Thereafter the reaction solution was diluted with 1 M NaCl (300 µL) 
and reacted with 0.011 M 3-methyl-2-benzothiazolinehydrazone-hydrochloride (MBTH, 
500 µL, 50 °C, 15 min), followed by the addition of 0.031 M FeCl3 (500 µL, 50 °C, 20 
min). Absorbances of the resultant solutions were determined by UV spectroscopy (660 
nm, Shimadzu UV 1601-PC) using eluates from control gels (n = 4, pooled) as 
background readings to negate possible PEG effects.  Standard Hep and HS solutions 
were made and treated in an identical manner (0–600 µg Hep/HS in 250 µL DI) to obtain 
a standard curve which was used to calculate the concentration of Hep/HS (mg/mL 
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eluate) released. The theoretical Hep/HS content (mg/g gel) was determined by 
normalizing the Hep/HS concentration released with Wg and coefficients of determination 
(R2-values) of elution curves were determined by linear trend line fitting in Microsoft 
Excel.  
 
2.12 Heparin and Heparan Sulfate Activity Assay 
 
The activities of acrylated and unmodified Hep/HS (n = 3), as well as the activities of the 
eluates of all the gels (n = 3) were determined via thromboelastography (TEG) and 
rotational thromboelastometry (ROTEM). Both assays have the same fundamental 
principles and share many similarities, but differ in complexity, ease of use and cost.256–
258
 The results obtained are also not completely interchangeable due to differences in 
operating characteristics.259 Thromboelastography was performed based on previous 
studies in our laboratories, but studies were converted towards ROTEM because it is 
less sensitive to vibration, much more economical to use and it operates through 
automated pipetting which minimizes experimental error.260  The use of human blood 
was approved by the Human Research Ethics Committee of the University of Cape 
Town (UCT) after informed consent. 
  
2.12.1 Thromboelastography 
 
Hep/HS or Hep/HS-Ac (110 µL, 0.01 mg/mL in PBS1) was mixed with 1 mL citrated 
whole blood (WB, 3.2% sodium citrate tube; BD Medical, Johannesburg, RSA) and PBS1 
(110 µL in 1 mL WB) was used as control. The mixture (1 mL) was placed in a Kaolin-
coated vial (BD Medical, Johannesburg, RSA), followed by the addition of CaCl (20 µL, 
0.2 M). Of this solution, 340 µL was placed in a pre-warmed cup (37 °C) and the clotting 
parameters of the sample were determined by a TEG® haemostasis analyser (5000 
series). These parameters are illustrated in Fig. 18 - clotting time (R, time from start to 
when the waveform reaches 2 mm above baseline); clot formation time (K, time from 2 
mm above baseline to 20 mm above baseline); rate of clot strength build-up (α, alpha 
angle); and clot strength (maximal amplitude, MA).  The activity of the eluates was 
determined in a similar way using 110 µL eluates (normalized to 0.01 mg/mL with PBS1).   
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Figure 18: Characteristic TEG plot of whole blood.  The clotting time (R), clot kinetics (K, α) 
and clot strength (MA) are drawn in solid lines while the range of normal haemostasis of 
these parameters are indicated through dashed lines.  
 
2.12.2 Rotational Thromboelastometry 
 
INTEM, EXTEM, HEPTEM, APTEM, FIBTEM and NATEM experiments were performed 
using a ROTEM® delta (Viking Medical & Surgical Pty. Ltd., Edenvale, RSA). Hep/HS 
(110 µL, 0.05 mg/µL in PBS1) was mixed with 1 mL citrated WB and 300 µL thereof was 
placed in a cup, followed by the automated addition of initiators (summarized in Table 5). 
The activity of acrylated and modified Hep/HS (110 µL, 0.05 mg/µL in PBS1) was 
evaluated by INTEM and the activity of eluates (normalized with PBS1, 0.002 mg/mL) by 
NATEM (due to the lower concentration higher sensitivity was needed). For all ROTEM 
experiments PBS1 (110 µL in 1 mL WB) was used as control. 
 
Table 5: Summary of initiators for different ROTEM assays 
INTEM Intrinsic ROTEM phospholipid and ellagic acid (star-tem® and in-tem®) 
EXTEM Extrinsic ROTEM tissue factor  (star-tem® and r ex-tem®) 
HEPTEM Heparinise ROTEM lyophilised heparinase (in-tem® and hep-tem®) 
APTEM Aprotinin ROTEM aprotinin (r ex-tem® and t ap-tem®) 
FIBTEM Fibrinogen ROTEM cytochalasin D platelet inhibitor (r ex-tem® and fib-tem®) 
NATEM Native ROTEM Re-calcifier (star-tem®) 
 
 
time (min) 
a
m
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(m
m
) Normal haemostasis: 
R = 4-8 min 
K = 0-4 min 
α = 47°-74° 
MA = 54-72 mm 
 R     K 
α 
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2.13 Growth Factor Binding and Release 
 
Only Type 2D gels were evaluated for GF binding and release in vitro and in vivo. 
Although both bFGF and VEGF have shown to possess pro-angiogenic properties and a 
binding site for Hep and HS, VEGF has been shown to be a stronger angiogenic 
promoter and was therefore used in this project. 122,261–265 Gels (50 µL, n = 4) were made 
by reacting Hep/HS-Ac (0.03 mg in 5 µL PBS2) with VEGF (1 µL, 1 mg/mL), followed by 
the addition of 10PEG4SH (2.02 mg in 25 µL PBS2) and 20PEG8Ac (1.97 mg in 20 µL 
PBS2), and allowed to react for 1 hr at 37 °C. Gels were individually immersed in PBS2 
(500 µL, 1% BSA, pH = 7.4) with shaking (1 hr, 37 °C), whereafter the eluates were 
removed and stored at 4 °C. This was performed twice to remove GF that washed out 
after gelation. Gels were subsequently immersed in buffer (500 µL PBS2, 1% BSA, 
0.02% sodium azide) at 37 °C and eluates were collected and replaced by fresh buffer at 
regular intervals. Gels containing GF without Hep/HS and gels containing Hep/HS 
without GF (to validate the ELISA) were used as controls. 
 
The concentration VEGF released during the wash-out phase and over time was 
quantified using a human VEGF enzyme-linked immunosorbent assay (ELISA) kit (R&D, 
Minneapolis, MN, USA), as per manufacturer’s instructions. Briefly, a 96-well micro-plate 
was coated with mouse anti-human VEGF antibody (100 µL/well, 1.0 µg/mL in PBS2) 
and incubated overnight at RT. Thereafter the plate was washed with 0.05% Tween®20 
in PBS2 (pH = 7.2-7.4, 400 µL, 3 times) and blocked by PBS2 (300 µL, 1% BSA, pH = 
7.2-7.4, RT, 1 hr). Each eluate (100 µL, collected over time or from wash steps) were 
placed in a separate well, followed by the addition of four different solutions: biotinylated 
goat anti-human VEGF antibody (100 µL/well, 100 ng/mL in 1% BSA PBS2);  streptavidin 
conjugated to horseradish-peroxidase (100 µL/well, 100 ng/mL in 1% BSA PBS2); a 
H2O2 and Tetramethylbenzidine solution (1:1, 100 µL/well); and H2SO4 (2 M, 50 µL 
µL/well).  Each addition was followed by incubation (RT, 2 hr or 20 min). Thereafter the 
optical density was determined by a micro-plate reader (450 nm, wavelength correction 
at 570 nm). Human VEGF standard solutions were made and treated in a similar manner 
(31.3–2000 pg/mL in 1% BSA PBS2) to obtain a standard curve. The VEGF 
concentrations (ng/mL eluate) over time were calculated using the curve and R2-values 
were determined by linear trendline fitting in Microsoft Excel. 
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2.14 Curve Fitting 
 
In order to establish the release mechanism of covalently incorporated Hep/HS and GF 
the following mathematical models were investigated: Zero and first order release 
models represented by Eq. 16 and Eq. 17, respectively.156 
 
o  oL	L    Eq. 16   ytojg,  ytoL − F   Eq. 17 
  
Where Q0 is the initial amount of Hep/HS, Qt is the cumulative amount of Hep/HS 
released at time t, and k0 and k1 is the zero and first order rate constants, respectively. 
As Qrem,t relates to the amount of Hep/HS remaining at time t, Eq. 17 was modified to 
describe the amount released (Eq. 18). 
 
o  oL(F − F)   Eq. 18  
 
The coefficients of determination (R2) were calculated by linear trendline fitting in 
Microsoft Excel and GraphPad Prism, either directly (cumulated release versus elution 
time) for zero order release or by using the natural logarithm of the amount versus 
elution time for first order release.  Initial burst release data (day 1-2) and data obtained 
after gel disintegration (after day 22) were excluded and no Y-axis intersections were 
guided through zero.   
 
2.15 In Vivo Evaluation in Rat Subcutaneous Model 
 
Type 2D gels containing Hep (50 µL, n = 6) were prepared as for GF experiments, 
except that before polymerization it was absorbed into PU disks and incubated for 1 hr 
(37 °C), under sterile conditions. Sterility of the procedure was tested by incubating (37 
°C, 3 days) disks, as prepared for implantation, in MCDB 131 medium (containing trace 
elements and L-glutamine) with 10% Fetal Bovine Serum (FBS).  The absence of 
bacteria, viruses and fungi were determined through microscopic evaluation. The in vivo 
effects of the different samples (summarized in Table 6) were evaluated based on 
cellular infiltration, collagen deposition, angiogenesis and inflammation. 9,53,245 No in vivo 
tests were performed on HS and all samples were implanted per rat as internal controls.  
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Table 6: Different samples prepared for in vivo evaluation in rat subcutaneous model 
Sample name Content Effect tested 
PU  Control disk without gel   Surgical intervention and foreign 
body response caused by disk 
PU + PEG-Ac/SH Disk with Type 2D control gel Gel swelling and degradation  
PU + PEG-Ac/SH/Hep Disk with Type 2D NI gel NI Hep  
PU + PEG-Ac/SH + GF Disk with Type 2D control gel 
and GF 
Release of GF from gel 
PU + PEG-Ac/SH/Hep-Ac Disk with Type 2D CI gel Modified Hep CI into gel  
PU + PEG-Ac/SH/Hep-Ac + GF Disk with Type 2D CI gel and GF GF release from gel through CI 
Hep 
 
Animal experiments were approved by the Animal Research and Ethics Committee of 
UCT and complied with the Guide for the Care and Use of Laboratory Animals. Wistar 
rats (male) were obtained from the UCT Animal Unit and weighed to establish baseline 
weights for post-operative welfare monitoring. Anaesthesia was induced by placing the 
animal in an inhalation chamber with 5% isoflurane air flow for 3 min, and maintained 
throughout the procedure by nose cone delivery (1.5% Isoflurane, 1.5 l/min oxygen 
output, 750 mmHg, 21 °C).  Body temperature was maintained by placing the animal on 
a custom made heating pad (37°C). The surgical area was shaved and sterilised with 
iodine, whereafter 0.05 mg/kg buprenorphine was given preoperatively as analgesic. All 
surgical procedures were performed using aseptic techniques.  
 
Longitudinal incisions (6, 3 each side, 1 cm) were made on either side of the dorsal 
midline and pockets (1.5 cm in depth) were blunt dissected subcutaneously at each 
incision.  Thereafter samples were placed each within its own pocket (each rat receiving 
only one disk of each group) and incisions were closed with monofilament nylon 4/0 
stitches (interrupted sutures were placed in a subcuticular fashion with a buried knot). 
Rats were observed until fully conscious and received a buprenorphine injection (0.05 
mg/kg, 24 hr after operation). Prior to retrieval of the tissue at predetermined time points 
(7, 14 and 28 days) the rats were killed whilst under general anaesthesia (inhalation of 
5% halothane in air) and death was ensured by cardiac puncture (1 mL saturated KCl 
injection). The samples with surrounding tissue were explanted, halved into equal semi-
cylindrical sections and fixed (one half of each disk in zinc fixative and the other in 10% 
buffered formalin, see Appendix A) for 5 days.   
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2.16 Histological Evaluation and Immunohistochemistry 
  
Fixed samples were processed through a graded alcohol (15-100%) procedure and 
embedded in paraffin wax.  Thereafter they were cut into 3 µm sections and baked on 
glass slides (60 °C, 30 min). These samples were dewaxed through 2,2,4-
trimethylpentane (3 times, 20 min each), agitated in descending alcohol concentrations, 
stained and mounted in Canada Balsalm on coated slides. Stains performed were 
hematoxylin (Merck, Damstadt, Germany) and eosin (BDH; WWR International, Poole, 
England) (H&E) to identify nuclei; Sirius red F3B and picric acid (picrosirius red stain) to 
identify collagen; as well as mouse anti-rat CD31 antibodies for immunohistochemistry 
labelling endothelial cells.  
 
Samples were observed and images captured with a Nikon eclipse 90i microscope with 
Digital Camera DXM-1200C (Nikon Corporation,Tokyo, Japan) and micrographs 
covering the entire disk were stitched together by automatic scanning (NIS Elements 
software). Image analysis was performed by training the Visiopharm Integrated Systems 
(Visiopharm A/S, Hørsholm, Denmark) software to automatically detect certain 
structures, but all analyses were assessed for accuracy by an observer and corrected 
manually where necessary. Tissue ingrowth was expressed as the ingrown area (tissue 
and nuclei) as a percentage of the available ingrowth area (excluding the PU); collagen 
deposition as the total collagen area relative to the ingrowth area; while angiogenesis 
was expressed as the number of capillaries and capillary area relative to the ingrown 
area.  
 
2.17 Statistical Analysis  
 
Results are expressed in text and represented in graphs as mean ± standard deviation 
(SD).  Continuous data were tested for normality with a Shapiro-Wilk test (Stata/SE 12.1 
software) and, where appropriate, analysed with a student’s unpaired t-test and multiple-
group analysis (one-way and two-way ANOVA) using GraphPad Prism. Significant levels 
for pairwise testing between categories were controlled by the Tukey’s HSD studentized 
range test and a level of p ≤ 0.05 was considered statistically significant 
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3 Results  
3.1 Modified Heparin/Heparan Sulfate 
 
Modified Hep/HS with acrylation percentages of 1-80% were obtained through different 
methods, with the largest degree of modification obtained through controlled addition of 
acryloyl chloride (AcCl) using a syringe pump.  Methacrylated Hep/HS (Hep/HS-MA) of 
11-13% and 11-19% were obtained through anhydride and epoxy chemistry, 
respectively. However, larger conversions of Hep/HS-MA were not achieved despite 
varying reaction conditions.  
  
3.2 Gel Formation 
 
Michael-type addition reactions (pH = 7.4, 37 °C) resulted in successful formation of 
Type 1 gels when Hep/HS-Ac (with acrylation percentages higher than 20%) were 
reacted with 10PEG4SH. Modified Hep/HS with acrylation lower than 20% did not form 
Type 1 gels through Michael-type addition reactions, despite varying temperatures (20-
50 °C), pH levels (pH = 6-10) and Ac/SH ratios.  Michael-type addition reactions (pH = 
7.4, 37 °C) resulted in successful formation of Type 2 gels – when 20PEG8Ac or 
20PEG8VS and 10PEG4SH were reacted together control gels (PEG-Ac/SH or PEG-
VS/SH) formed, while the addition of either Hep/HS or Hep/HS-Ac (40% acrylation) to 
these formulations (PEG-Ac/SH or PEG-VS/SH) led to the successful formation of non-
covalently (NI) and covalently incorporated (CI) gels, respectively. 
 
Photo-polymerization through UV irradiation resulted in successful gel formation using 
Hep/HS-MA or Hep/HS-Ac (< 20% acrylation) in solution with DMPA and NVP, except 
when the degree of modification was 3% or lower. Controls: UV irradiation of modified 
Hep/HS, a mixture of modified Hep/HS and NVP, or a solution of DMPA in NVP did not 
result in gelation. A solution of modified Hep/HS and DMPA only showed initial gel 
formation after prolonged irradiation (30-40 min).  
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3.3 Rheological Characterization  
3.3.1 Gelation time 
 
The storage (G’) and loss moduli (G’’) of PEG-Ac/SH (as example) when subjected to 
oscillatory time sweep during gelation are shown in Fig. 19, as plotted over time. The 
crossover occurred at 7.2 ± 0.3 min, which was taken as the gelation time. This plot was 
characteristic for all gel formulations.248,266   
 
 
Figure 19: Characteristic plot of in situ gelation of all gels (Type 1 and 2 gels, PEG-Ac/SH 
in this case) during oscillatory time sweep (1 Hz; 2% strain; 25 °C) 
 
Regarding Type 1 gels, the gelation time of HS-Ac/SH was 1.3 ± 0.2 min (p = 0.0112) 
shorter than Hep-Ac/SH (Fig. 20 a). Type 2D and 2N gels formed on average at 7.2 ± 
0.3 min and 3.1 ± 0.1 min, respectively. Gelation time for Type 2N gels was therefore 58 
± 2% (p < 0.0001) shorter than Type 2D (Fig. 20 b). No significant difference was 
observed between gelation times of either different Type 2D or Type 2N gel 
formulations.   
 
Figure 20: Gelation times of Type 1 (a) and Type 2 (b) gels obtained through oscillatory 
time sweep (n = 3; NS shows p > 0.05; * shows p < 0.05; ** shows p < 0.0001) 
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3.3.2 Viscoelasticity  
 
When subjected to oscillatory stress sweep, the storage moduli (G’) of Type 1 gels were 
constant at 4391 ± 441 Pa (Fig. 21 a), until the ultimate stress level (sharp decrease) 
was reached at 566 ± 92 Pa. Storage moduli for Type 2 gels were also constant, but at 
different G’ values for different gel formulations (ranging from 6560 ± 27 Pa to 10460 ± 
353 Pa).  The ultimate stress level in Fig. 21 b was reached at 897 ± 145 Pa on average. 
 
 
 
Figure 21: Linear viscoelastic region determination of Type 1 (a) and Type 2 (b) gels 
obtained through oscillatory stress sweep (1Hz; 25 °C) 
 
The G’ of Hep-Ac/SH (as example), subjected to frequency sweep at a constant shear 
stress (250 Pa), exhibited a plateau in the range 1-80 Hz (Fig. 22). This was followed by 
a slight increase at higher frequencies (80-100 Hz). Loss modulus (G’’), slightly erratic in 
nature, was one to two magnitudes lower than G’ over all measured frequencies and 
characteristic for all equilibrium swollen gels of different gel formulations. 
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Figure 22: Characteristic plot of all equilibrium swollen gels (Type 1 and 2 gels, Hep-Ac/SH 
in this case) during oscillatory frequency sweep 
 
Storage moduli of Type 1 gels showed that Hep-Ac/SH was 752 ± 105 Pa higher than 
HS-Ac/SH (19 ± 4%, p = 0.0064, Fig. 23 a). Regarding Type 2 gels, no significant 
differences were observed between either G’ values of Type 2D control, NI and CI gels 
or between G’ of Type 2N control, NI and CI gels. Type 2N gels had on average 40 ± 6% 
(p < 0.05) higher G’ values than their corresponding Type 2D gels in Fig. 23 b.  
 
Figure 23: Storage moduli of Type 1 (a) and Type 2 (b) gels obtained through oscillatory 
frequency sweep. (n = 3; NS shows p > 0.05, * shows p < 0.05) 
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significant difference was observed in Fig. 24 a. No significant difference between Hep-
Ac/SH and HS-Ac/SH was observed after day 3. 
 
All Type 2 gels underwent an approximate 128 ± 37% (p < 0.0001) increase in Q 
between 0 to 3 days (Fig. 24 b).   Type 2D gels continued to increase a further 145 ± 
47% (p < 0.0001) on average between 3 and 17 days, whereafter gels were too 
disintegrated for further volume determination. There were no significant differences 
between different Type 2D gels. Swelling ratios (Q) of Type 2N gels stayed constant at 
18.2 ± 1.1 from day 3 to 36, with no significant differences between different Type 2N 
gels. At 17 days the Q for Type 2D gels was, on average, 173 ± 30% (p < 0.0001) higher 
than Type 2N gels.  
 
   
Figure 24: Swelling ratios (Q) of Type 1 (a) and Type 2 (b) gels during incubation at 37 °C in 
PBS (n = 3)  
 
3.4.2 Swelling ratio 2  
 
Type 1 gels showed rapid initial swelling during the first day (2.6 ± 0.1; p < 0.0001) 
subsequent steady increase to day 72 (Fig. 25).  At day 15 and onwards, Hep-Ac/SH 
had significantly higher swelling ration 2 (SR) values than HS-Ac/SH and the final SR of 
Hep-Ac/SH was 50.5 ± 7.6% (p < 0.0001) higher than HS-Ac/SH at 72 days.     
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Figure 25: Swelling ratio (SR) of Type 1 gels during incubation at 37 °C in PBS (n = 4)  
 
Type 2D gels showed rapid initial swelling within the first 6 hours (p<0.05), subsequent 
steady increase to 3.5 ± 0.9 at 21 days.  Thereafter rapid degradation followed to such 
an extent that further accurate measurements were difficult (Fig. 26). These gels 
underwent a 252 ± 39% (p < 0.0001) increase in SR during day 0 to 21, with no 
significant differences between the different Type 2D gel formulations at any time point.  
Similarly, rapid initial swelling was observed with Type 2N gels, but the increase was 
only significant after 24 hours. Retention of equilibrium values at 1.2 ± 0.1 followed after 
the first day, with no significant differences between the different Type 2N gel 
formulations. These gels did not show signs of degradation for up to six months (data 
not shown). At day 21 the SR of Type 2D gels was 176 ± 29% (p < 0.0001) higher than 
Type 2N gels.  
 
 
Figure 26: Swelling ratios (SR) of Type 2 gels during incubation at 37 °C in PBS (n = 4)  
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3.4.3 Mesh Size  
 
The mesh sizes of Type 2 gels followed similar trends to Q over time. The average initial 
mesh size of the gels was 44.6 ± 3.1 Å, whereafter it increased by 170 ± 47% (p < 
0.0001), on average, during the first three days (Fig. 27). Thereafter mesh sizes of Type 
2D gels continued to increase a further 92 ± 14% (p < 0.0001) between 3 and 17 days 
towards an average mesh size of 245.6 ± 13.9 Å, There were with no significant 
differences between different Type 2D gels. Mesh sizes of Type 2N gels did not increase 
significantly between 3 and 36 days (average mesh size of 116.3 ± 7.1 Å during that 
time), and there were no significant differences between different Type 2N gels.  At 17 
days, the mesh sizes of Type 2D gels were, on average, 118 ± 16% (p < 0.0001) higher 
than Type 2N gels. 
 
Figure 27: Mesh size of Type 2 gels during incubation at 37 °C in PBS (n = 3)  
 
3.5 Heparin and Heparan Sulfate Elution 
 
Eluates from Type 1 gels in Fig. 28 were characterized by initial burst releases of 2 ± 1% 
(p = 0.0098) Hep and 12 ± 2% (p < 0.0001) HS during the first day, whereafter the gels 
followed zero order Hep (R2 ≥ 0.96) and HS (R2 ≥ 0.93) release kinetics for the recorded 
period. Although the cumulative HS release was significantly higher than that of Hep 
between 1 to 41 days, there was no significant difference between the incremental 
amount of HS and Hep released during that period. Thereafter the incremental amount 
of Hep release was 41 ± 6% (p = 0.025) to 127 ± 7% (p < 0.0001) higher than the 
incremental HS release (41 to 72 days). During the recorded period Hep-Ac/SH and HS-
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Ac/SH released 48 ± 5% Hep and 44 ± 5% HS of the initial amount, respectively (p < 
0.0001).  
 
Figure 28:	Cumulative release of Hep/HS from Type 1 gels during incubation in PBS at 37 
°C over a 72 day period (n = 4) 
 
Hep and HS release from Type 2 gels are shown in Fig. 29. NI gels showed rapid burst 
release, with over 90% of the initial amount of the Hep (93 ± 7%) and HS (92 ± 8%) 
eluted during the first 36 hours (p < 0.0001). No significant amount of Hep and HS were 
released from Type 2D NI gels (PEG-Ac/SH/Hep and PEG-Ac/SH/HS) between 2 to 21 
days, whereafter a burst release was showed upon gel dissolution (p < 0.0001). Type 2N 
NI gels (PEG-VS/SH/Hep and PEG-VS/SH/HS) released no Hep and HS between 2 to 
56 days (p > 0.05). 
 
CI gels showed small initial burst release during the first day (but to a significantly 
smaller extent than the NI gels) since only 16 ± 3% (p = 0.0074) and 21 ± 2% (p = 0.004) 
of the initial amounts of Hep and HS eluted, respectively. Thereafter Hep/HS release 
from Type 2D CI gels (PEG-Ac/SH/Hep-Ac and PEG-Ac/SH/HS-Ac) followed a zero 
order (R2 ≥ 0.88 and R2 ≥ 0.96, respectively) release model. A further 57 ± 13% (p < 
0.0001) Hep and 72 ± 7% (p < 0.0001) HS were released from these gels between 1 and 
21 days. The cumulative HS release was 21 ± 16% (p = 0.0008) higher than the 
cumulative Hep release at day 21, whereafter a significant burst release of the remaining 
Hep/HS content occurred with natural gel dissolution.  After the initial burst, the 
sustained Hep/HS release from Type 2N CI gels (PEG-VS/SH/Hep and PEG-VS/SH/HS) 
followed a first order (R2 ≥ 90 and R2 ≥ 0.84, respectively) fashion, with a total of 85 ± 
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12% (p < 0.0001) Hep and 90 ± 8% (p < 0.0001) HS released, respectively over the 
recorded period (56 days).  
 
 
Figure 29: Cumulative release of Hep/HS from Type 2 gels during incubation in PBS at 37 
°C (n = 4) 
 
3.6 Heparin and Heparan Sulfate Activity  
 
The clotting kinetic parameters in Fig. 30 showed no significant difference in clotting time 
(R), clot kinetics (K, α) or clot strength (maximal amplitude, MA) between whole blood 
(WB) containing PBS, HS in PBS or HS-Ac in PBS. Thromboelastography (TEG) of Hep 
and Hep-Ac showed 66 ± 10% (p < 0.0001) and 44 ± 7% (p < 0.0001) higher R times 
than PBS, respectively; K values were prolonged (869 ± 154% and 350 ± 38% higher 
than PBS; p < 0.0001);  α values were 196 ± 10% and 86 ± 7% lower than PBS, (p < 
0.0001); while MA of Hep and Hep-Ac were 27 ± 2% and 21 ± 1% lower than PBS, 
respectively (p < 0.0001). Although the addition of acrylated and unmodified Hep/HS to 
PBS affected R, K, α and MA significantly, only clotting time (R) was used to represent 
Hep and HS activity in the remainder of the study. 
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Figure 30: Clotting kinetic parameters of virgin and modified Hep/HS (0.01 mg/mL PBS) 
measured by TEG (n = 3; NS shows p > 0.05; * shows p < 0.0001 against PBS and eluates 
with HS; ** shows p < 0.0001 against Hep-Ac)     
 
Of all the Rotational Thromboelastometry (ROTEM) assays that received initiators, the 
addition of PBS, Hep and HS to WB affected the coagulation profiles (Fig. 31 a) and 
clotting times (Fig. 31 b) of INTEM (intrinsic ROTEM) most significantly. Coagulation 
activity was therefore evaluated with INTEM for samples with Hep/HS concentrations of 
0.05 mg/mL. Although results obtained through INTEM were approximately 4 to 15 times 
shorter than NATEM (native ROTEM), increased clotting times obtained through NATEM 
showed even larger differences.  This made the discerning of small differences (at very 
low concentrations) possible. NATEM was therefore used for samples with Hep/HS 
concentrations of 0.002 mg/mL.  
 
Unmodified and acrylated Hep/HS subjected to INTEM showed no significant difference 
in the clotting times between HS and HS-Ac, both of which were 1.8 ± 0.5 min (64 ± 
17%; p = 0.0031) higher than PBS (Fig. 32). The clotting times of Hep and Hep-Ac were 
respectively 14.1 ± 1.3 min (535 ± 46%) and 5.5 ± 1.0 min (233 ± 38%) higher than PBS 
control (p < 0.0001). The clotting time of WB containing Hep was 91 ± 15% (p < 0.0001) 
higher than Hep-Ac. 
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Figure 31: The coagulation profiles (a) and clotting times (b) of WB with PBS, Hep and HS 
(0.05 mg/mL PBS) subjected to ROTEM. NATEM profiles are not shown due to increased 
times 
 
 
Figure 32: Clotting times of WB containing Hep/HS or Hep/HS-Ac (0.05 mg/mL in PBS) 
subjected to INTEM (n = 3; NS shows p > 0.05, * shows p < 0.0001 against PBS and eluates 
with HS; ** shows p < 0.0001 against Hep-Ac) 
 
Clotting times of WB containing eluates from Type 1 gels showed no significant 
difference between the clotting times of eluates from HS-Ac/SH at different time points 
(day 3, 31 and 72). At day 3 and day 72, the clotting times were 32 ± 2% (p = 0.01) and 
42 ± 17% (p = 0.002) higher than the PBS control, respectively (Fig. 33).  The clotting 
times of eluates from Hep-Ac/SH were 74 ± 6%, 102 ± 16% and 148 ± 1% higher than 
the PBS control at 3, 31 and 72 days, respectively (p < 0.0001).   
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Figure 33: Clotting times of WB containing eluates of Type 1 gels subjected to TEG (n = 3; 
* shows p < 0.001 against PBS and eluates with HS) 
 
Regarding eluates from Type 2 gels, no significant difference was observed between the 
clotting times of WB with eluates from PEG-Ac/SH/HS, PEG-VS/SH/HS and PBS at any 
of the time points (Fig. 34). Clotting times of eluates from PEG-VS/SH/Hep and PEG-
Ac/SH/Hep were 9.9 ± 1.0 min (p < 0.0001) and 1.6 ± 0.1 min (p < 0.0001) higher than 
PBS, respectively at day 1 and increased significantly between day 1 and 3.  However, 
at day 5 the clotting times of all NI gels were similar to the PBS control.   
 
 
Figure 34: Clotting times of WB containing eluates from NI gels subjected to NATEM (n = 
3; NS shows p > 0.05; * shows p < 0.05 against PBS and eluates with HS)  
 
Similar to NI gels no significant differences were observed in the clotting times of PEG-
Ac/SH/HS-Ac, PEG-VS/SH/HS-Ac and PBS over all time points (Fig. 35). Clotting times 
of PEG-Ac/SH/Hep-Ac were 81 ± 8% (p = 0.004) higher than PEG-VS/SH/Hep-Ac at day 
1, but did not differ significantly thereafter. These clotting times were between 1.6 ± 0.6 
min (56 ± 18%; p = 0.047) and 5.1 ± 1.9 min (183 ± 20%; p = 0.0004) higher than the 
PBS control.  
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Figure 35: Clotting times of WB containing eluates from CI gels subjected to NATEM (n = 
3; NS shows p > 0.05; * shows p < 0.05 against PBS and eluates with HS)  
 
3.7 Growth Factor Binding and Release 
 
 
Figure 36: Growth factor washout from PEG-Ac/SH, PEG-Ac/SH/Hep-Ac and PEG-
Ac/SH/HS-Ac (n = 4; * shows p<0.0001 against all other samples) 
 
Growth factor (GF) release from PEG-Ac/SH/Hep-Ac and PEG-Ac/SH/HS-Ac (Type 2D 
CI gels) showed zero order (R2 ≥ 0.91 and R2 ≥ 0.99, respectively) release over the 
whole elution period recorded (Fig. 37). The GF release rate from PEG-Ac/SH/HS-Ac 
was on average 69 ± 11% (p < 0.0001) higher than PEG-Ac/SH/Hep-Ac over the 
recorded period (12 days). At day 12, 8 ± 1% and 13 ± 1% of the total amounts of 
incorporated GF were released from PEG-Ac/SH/Hep-Ac and PEG-Ac/SH/HS-Ac, 
respectively (p < 0.0001). GF release from PEG-Ac/SH (Type 2D control gels) showed 
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an initial burst (day 0-1), during which 3 ± 1% of incorporated GF was released, and was 
followed by a first order release profile (R2 ≥ 0.96). These gels released 11 ± 1% of the 
total amount of incorporated GF over the 12 day period. No release was observed from 
PEG-Ac/SH/Hep-Ac without GF (negative control).  
 
 
Figure 37: Growth factor elution from PEG-Ac/SH, PEG-Ac/SH/Hep-Ac and PEG-Ac/SH/HS-
Ac (n = 4) 
 
3.8 In Vivo Evaluation in Rat Subcutaneous Model  
 
Qualitative assessment of hematoxylin and eosin (H&E) stains evinced that porous 
polyurethane (PU) disks without gel showed near-complete ingrowth at 7 days, while PU 
disks containing different gel formulations (for example PU + PEG-Ac/SH/Hep-Ac + GF 
in Fig. 38) suggested an increase in the area occupied by ingrown tissue relative to the 
available ingrowth area (scaffold area excluding the PU) over time. All samples were 
fully ingrown at 28 days. This was supported by quantitative data in Fig. 39 – explanted 
PU disks without gel were almost completely ingrown (97 ± 3%) at 7 days, while the 
disks with different gel formulations contained only 3 ± 2% to 35 ± 16% (p < 0.0001) 
tissue. At 14 days disks containing gels had 61 ± 16% to 95 ± 6% ingrown tissue, while 
all samples were fully ingrown (99 ± 1%) at 28 days. Between day 14 and 28 only PU + 
PEG-Ac/SH/Hep, PU + PEG-Ac/SH/Hep-Ac and PU + PEG-Ac/SH/Hep-Ac + GF (gel 
combinations with Hep) had a significant amount of ingrowth to complete.  
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Figure 38: Representative micrographs of H&E stained sections of PU + PEG-Ac/SH/Hep-
Ac + GF showing cellular and tissue ingrowth of the porous scaffolds at 7 (a), 14 (b) and 28 
(c) days rat subcutaneous implantation 
 
 
Figure 39: Ingrown area relative to ingrowth area of different explanted samples at 
different time points.  (n = 6; NS shows p > 0.05; * shows p < 0.0001 against day 14; ** 
shows p < 0.05 against day 28)    
 
Picrosirius red stains (PU + PEG-Ac/SH/Hep-Ac + GF as example) in Fig. 40 suggested 
an increase in collagen deposition (stained red) over time qualitatively, with or without 
incorporated gel formulations. Quantitative analysis (Fig. 41) supported this by showing 
similar trends to those obtained through H&E staining, with the exception of PU disks 
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without gel containing only 13 ± 3% collagen deposition relative to ingrowth area at 7 
days (as opposed to 42 ± 1% at 28 days). Moreover the total collagen deposition areas 
for all the samples were only 33 ± 3% to 42 ± 1% of the possible ingrowth area at 28 
days (as opposed to full ingrowth for H&E stains). 
 
      
Figure 40: Representative micrographs of picrosirius red stained sections of PU + PEG-
Ac/SH/Hep-Ac + GF showing collagen deposition of the porous scaffolds at 7 (a), 14 (b) 
and 28 (c) days rat subcutaneous implantation 
 
 
Figure 41: Collagen deposition relative to ingrowth area of different explanted samples at 
different time points (n = 6; * shows p < 0.005 against day 14; ** shows p < 0.0001 against 
day 28 
 
Qualitative assessment of vessel ingrowth into PU disks containing gel (Fig. 42) 
indicated an increase in CD31-positive endothelial cells constituting capillary vessels 
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when GF (d) or Hep-Ac (e) was added to the gel (PEG-Ac/SH), but the largest increase 
in capillary vessel ingrowth was observed when Hep-Ac and GF (f) were both added. 
The first two slides (i and ii) are examples of what were counted as vessels. 
 
 
   
 
  
Figure 42: Representative micrographs of CD31 stained sections of PU (a), PU + PEG-
Ac/SH (b), PU + PEG-Ac/SH/Hep (c), PU + PEG-Ac/SH + GF (d), PU + PEG-Ac/SH/Hep-Ac 
(e), and PU + PEG-Ac/SH/Hep-Ac + GF (f) showing vascularization of the porous scaffolds 
at 28 days rat subcutaneous implantation; (i) and (ii) are examples of vessel count 
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These findings were corroborated by quantitative data (Fig. 43 a), which showed that the 
number of capillaries relative to the ingrown area in PU + PEG-Ac/SH/Hep-Ac + GF was 
between 28 ± 10% (p = 0.044) to 694 ± 44% (p < 0.0001) higher than in all the other 
samples. Although the number of capillaries present in PU + PEG-Ac/SH + GF and PU + 
PEG-Ac/SH/Hep-Ac were significantly lower than in PU + PEG-Ac/SH/Hep-Ac + GF, it 
was still between 46 ± 11% (p = 0.030) to 511 ± 59% (p < 0.0001) higher than in the 
other samples.  The capillary area relative to the ingrown area of PU + PEG-Ac/SH/Hep-
Ac + GF was between 54 ± 33% (p = 0.012) to 349 ± 45% (p < 0.0001) higher than in all 
the other samples (Fig. 43 b).  There was no significant difference in the capillary area of 
PU disks (without gel) and all the other samples, excluding PU + PEG-Ac/SH/Hep-Ac + 
GF. However PU + PEG-Ac/SH/Hep-Ac was, on average, 123 ± 36% (p = 0.009) higher 
than PU + PEG-Ac/SH and PU + PEG-Ac/SH/Hep. 
 
   
Figure 43: Quantification of blood capillaries in porous PU scaffolds, showing the number 
of capillaries relative to ingrown area (a) and total capillary area as a percentage of the 
ingrown area (b) (n = 6; * shows p < 0.05 against all other samples; ** shows p < 0.05 
against PU and p < 0.0001 against PU + PEG-Ac/SH and PU + PEG-Ac/SH/Hep; *** shows p 
< 0.05 against PU + PEG-Ac/SH/Hep-Ac)  
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4 Discussions 
 
This work showed how the controlled release of active heparin or heparan sulfate 
(Hep/HS) could be achieved by covalent incorporation into spontaneously forming 
hydrogels, capable of controlled growth factor (GF) delivery to improve angiogenesis in 
vivo. Specifically: (i) 20PEG8Ac and 20PEG8VS copolymers were synthesized by 
nucleophilic substitution reactions, (ii) Hep and HS were acrylated by Schotten-Baumann 
reactions using acryloyl chloride (AcCl), (iii) hydrogels were formed by Michael-type 
addition reactions between acrylated Hep/HS (Hep/HS-Ac) and PEG tetra-thiols 
(10PEG4SH), to form Type 1 gels, and between the 20PEG8Ac and 20PEG8VS 
copolymers and 10PEG4SH to form Type 2D and 2N gels, respectively, with or without 
the covalent incorporation of Hep/HS, (iv) gel properties (gelation time, viscoelasticity, 
swelling, crosslink density and mesh size) were retained and not significantly influenced 
by the addition of Hep/HS-Ac, (v) Hep/HS was eluted from the hydrogels in a controlled 
manner and with retained activity (the anticoagulative properties of eluates from gels and 
their eluates were controlled as well), (vi) GFs were bound to Hep/HS hydrogels and 
released in a controlled manner, and (vii) these hydrogels were successful at improving 
angiogenesis in a rat subcutaneous model. 
 
4.1 Multi-arm PEG copolymers 
 
Polyethylene glycol copolymers were obtained in conversions of 93-94%, which is 
similar to previously reported for 20PEG8Ac and 20PEG8VS synthesis in 
literature.47,80,267 In the current project average yields were obtained and can be ascribed 
to the extensive purification method used - purification was performed by three 
subsequent precipitation steps and dialysis, as opposed to only one precipitation step 
performed in previous studies.47  
 
4.2 Modification of Heparin/Heparan Sulfate 
 
Of the different Hep/HS modification methods investigated in this project, the Schotten-
Baumann reaction using AcCl was preferred due to high conversions and yields 
obtained.  However, acrylic acid formed due to the high reactivity of AcCl with water 
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which affected the pH of the solution and, consequently, the degree of acrylation. A 
syringe pump was therefore used to control AcCl addition and ensure a stable pH 
between 8 and 9 (favouring the transesterification reaction).35,130,268 Benefits of this 
method include its high conversion (up to 80% acrylation), high yields, simplicity and 
short reaction times (1-2 hours) in comparison to the other methods investigated. Kumar 
and Gross also obtained as high conversions by using a similar method to acrylate 
hyaluronic acid (HA).130 Since the Ac groups were attached directly to the carbohydrate 
backbone, and not via spacers as previously reported by various researchers,69,268–271 
Hep/HS could be released in its original, unmodified form during hydrolysis. Anhydride 
and epoxy chemistries were not further used due to the low conversions obtained –  low 
reactivity of methacrylic anhydride with Hep/HS hydroxyls73,250 resulted in low 
methacrylation percentages (11-13%), while the competing transesterification and ring 
opening reactions69,268 (apparent from NMR analysis of products from reactions with 
glycidyl methacrylate) resulted in the presence of undesirable spacers.  
 
4.3 Gel Formation 
 
The successful formation of Type 1 gels (Hep-Ac/SH and HS-Ac/SH) and Type 2D and 
2N control gels (PEG-Ac/SH and PEG-VS/SH, respectively) through Michael-type 
addition reactions can be ascribed to the presence of  the crosslinker thiols (10PEG4SH, 
acting as the nucleophile) and α,β-unsaturated end-groups (VS or Ac) of functionalized 
Hep/HS and/or PEG (rendering the terminal carbon electrophilic).82,94,96,102,272,273 
Hydrogels of these types were previously developed by Hubbell et al.47,68 and variations 
by numerous other researchers.59,81,86,94,97,142,213 The covalent and non-covalent 
incorporation of Hep/HS into Type 2 gels did not significantly influence the gelation due 
to the small amount of Hep/HS or Hep/HS-Ac added (1.5m% of 4m% copolymer). 
 
Heparin/HS with 3% (meth)acrylation or lower did not result in gelation upon irradiation 
since it theoretically represents less than one Ac moiety per Hep/HS chain. It was 
however expected that Hep/HS-MA and Hep/HS-Ac (with acrylation lower than 20%) 
would spontaneously form gels through Michael-type addition reactions with 10PEG4SH, 
since 20% (meth)acrylation theoretically accounts for approximately six functionalized 
groups.12,53,69,73,130 Together with NMR results, the gelation of Hep/HS-MA and Hep/HS-
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Ac (all acrylation percentages higher than 3%) through photo-polymerization confirms 
successful Hep/HS modification.  
 
4.4 Rheological Characterization 
4.4.1 Gelation time 
 
The slightly faster gelation time of HS-Ac/SH than Hep-Ac/SH might be due to the less 
ionic nature of HS caused by its less sulfated structure.36,227 This was however not 
further investigated since the gelation times of Type 1 gels (5.3 min and 4.0 min for Hep-
Ac/SH and HS-Ac/SH, respectively) are both in the range (3 to 10 minutes) obtained for 
similar gels formed by previous researchers.35   
 
Gelation times of Type 2 gels are in expected ranges (7.2 min and 3.1 min for Type 2D  
and 2N gels, respectively) as obtained in similar studies by Zustiak and Leach.81  The 
shorter gelation times of Type 2N gels in comparison to Type 2D gels are due to the 
higher relative reactivity of VS (in comparison to Ac) towards thiols, since the sulfone 
groups are more electron deficient and have a higher electron withdrawing capability 
than the carbonyl groups of Ac.274–276 In a study by Chatani et al. they found that the 
reaction rate between VS and thiols was approximately seven times higher than 
between Ac and thiols.275 The addition of unmodified or acrylated Hep/HS not 
significantly affecting the gelation time was expected, since the amount added was very 
small (1.5m% of 4m% copolymer) and the acrylates present on the Hep/HS-Ac were 
accounted for by the stoichiometric amount of thiols added.  
 
4.4.2 Viscoelasticity   
 
The existence of complete crosslinked networks in the equilibrium swollen gels are 
confirmed by the independency of storage and loss moduli (G’ and G’’) on frequency in 
the studied range (0.01-100 Hz).35 These gels perform almost as ideal elastic materials 
since G’ exceeds G”,277 while the slight increase in G’ at higher frequencies (above 80 
Hz) can be ascribed to gel stiffening.248 The slightly higher G’ value of Hep-Ac/SH, in 
comparison to HS-Ac/SH (4767 Pa and 4015 Pa for Hep-Ac/SH and HS-Ac/SH, 
respectively), could be due to the greater ionic nature of Hep which results in greater 
water uptake and swelling (as also seen by the SR curve in Fig. 25), causing a greater 
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osmotic pressure and thus stiffer gel at the time of measurement.278 Storage moduli of 
Type 1 gels are however in similar ranges as those of gels developed by researchers 
using similar precursors.35   
 
The higher storage moduli of Type 2N gels (9914 Pa) than Type 2D gels (7073 Pa) is 
ascribed to the greater conversion and better crosslink density achieved at the time of 
measurement, due to the higher reactivity of VS than Ac towards thiols.275,276 Although 
these results are 10-fold lower than the G’ found in studies by Lutolf and Hubbel, who 
crosslinked 20PEG4VS with dithiols68, Tae et al. showed that an increase in the amount 
of crosslinking sites (4-arm to 8-arm) increased G’ by more than 10-fold.97  Storage 
moduli of Type 2 gels evinced again that the presence of unmodified or acrylated 
Hep/HS did not significantly influence the viscoelastic properties and stiffness of the 
gels. 
 
4.5 Hydrogel Swelling 
 
Initial swelling (swelling ratio 1 and 2, SR and Q) observed for Type 1 gels was due to 
equilibrium water uptake, whereafter continued swelling followed due to the steady 
decrease in crosslink density caused by hydrolysis of the relatively labile β-thio-ether 
ester linkages. The significantly higher overall swelling of Hep-Ac/SH than that of HS-
Ac/SH (by approximately 150%) can again be ascribed to the greater ionic strength of 
Hep leading to greater water uptake and swelling, as well as a possible difference in 
acrylation percentage.278 However, the Q values of both gels at day 3 (24.7 on average) 
are similar to studies using 40% thiolated Hep and diacrylated PEG for gel synthesis.97  
 
Although all Type 2 gels underwent rapid initial swelling due to absorbance of 
equilibrium amounts of water,64,252,279 Type 2D gels experiencing a more rapid initial 
swelling (as opposed to Type 2N gels) can be ascribed to the carbonyl oxygen of the 
ester, a strong hydrogen bond acceptor, which results in faster water uptake.81  As with 
Type 1 gels, the degradable nature of gels consisting of 20PEG8Ac copolymer was due 
to hydrolysis of the β-thio-ether ester bonds.102,272 Rapid disintegration after 21 days can 
be ascribed to the steady decrease in crosslink density caused by hydrolysis as well as 
bulk degradation – due to the high water content of the gels the probability for each ester 
bond to be broken via hydrolysis was the same.81  On the other hand, Type 2N gels 
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maintaining constant swelling ratios post-equilibrium confirms the stability of these thio-
ether sulfone bonds toward hydrolytic degradation in vitro.94,275,276,280 These findings are 
similar to those obtained in previous work by our group, during which SR values of 3.4-
3.6 and 1.7-2.1 were obtained for Type 2D and 2N gels, respectively after 12 days (in 
the current study the SR is 3.5 and 1.3 after 21 days).213 The values of Q also correlate 
well with gels studied by DuBose et al. who thiolated fluoroscopic probes, incorporated 
them into gels consisting of 20PEG8Ac crosslinked with dithiothreitol (DTT) and 
recorded Q values in the range of 18-40 between day 8 and 12.86 It is important to note 
that since the covalent and non-covalent incorporation of Hep/HS did not significantly 
influence the SR or Q of Type 2 gels, the presence of Hep/HS did not significantly 
disrupt the network structure, degree of cross-linking, hydrophilicity or degradation of the 
gels.81 
 
The initial increases in the mesh sizes of Type 2 gels were not necessarily due to bond 
breaking, but rather as a result of stretching of the polymers in the gel network, while 
further increases in the mesh sizes of Type 2D gels resulted from bond breaking during 
hydrolysis.253  Since the initial mesh size of the gels was 44.6 ± 3.1 Å on average, which 
is higher than the hydrodynamic diameters of Hep/HS and VEGF (9 ± 1 Å 281 and 38 ± 1 
Å 282, respectively), it can be assumed that the diffusion of non-covalently or 
incompletely incorporated Hep/HS or VEGF caused the initial burst release, whereafter 
the delivery of covalently incorporated Hep/HS could continue in vitro. In a study by 
Bracher et al., who crosslinked matrix metalloproteinase (MMP) with 20PEG4VS,244 the 
gels had higher average mesh sizes after equilibrium swelling due to the lower crosslink 
density of copolymers used (4-arms as opposed to 8-arms in the current project, for the 
same molecular weight) as per Flory-Stockmayer’s theory.68,86,217,275  
 
4.6 Heparin and Heparan Sulfate Elution 
 
Type 1 gels: The initial Hep/HS burst release from Type 1 gels is apparent from swelling 
kinetics, while the zero order release obtained after covalent incorporation of Hep or HS 
in hydrogels is usually unattainable by simple incorporation, swelling or diffusion 
controlled release mechanisms.86,154,155 The slightly greater initial elution of HS in 
comparison to Hep was not expected since the levels of acrylation of both were 40%, but 
can be attributed to incomplete covalent incorporation of HS-Ac during gel formation 
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(since the G’ of equilibrium swollen HS-Ac/SH was also significantly lower than Hep-
Ac/SH) or non-idealities, such as multiple arms from the same crosslinker reacting with 
Ac to form primary cycles and diffuse from the gel upon immersion. This was however 
not investigated as it was considered outside the scope of this study.  
 
Type 2 gels: Although a small amount of Hep and HS was initially released from CI gels 
(PEG-Ac/SH/Hep-Ac, PEG-Ac/SH/HS-Ac, PEG-VS/SH/Hep-Ac and PEG-Ac/SH/HS-Ac) 
probably due to incomplete incorporation and/or rapid equilibrium swelling, the amount 
was drastically lower than the initial burst from NI gels (PEG-Ac/SH/Hep, PEG-
Ac/SH/HS, PEG-VS/SH/Hep and PEG-Ac/SH/HS). This confirms the successful covalent 
incorporation of the majority of the Hep/HS-Ac. Elution of Hep and HS from NI gels is 
considered to be of burst release character, since the total amount of non-covalently 
bound Hep/HS diffused from the gel during the initial two days.  
 
The subsequent near linear, zero order release from Type 2D CI gels (PEG-Ac/SH/Hep-
Ac and PEG-Ac/SH/HS-Ac) can be ascribed to the degradation of the two different types 
of ester bonds, i.e. Hep/HS or 20PEG8Ac attached to 10PEG4SH.86 Primarily release 
refers to Hep/HS cleaved from the gel network through hydrolysis (due to β-thio-ether 
ester bonds) releasing it from the polymer matrix in its unmodified form,102 while 
secondary release occurred through cleavage of the β-thio-ether ester bonds linking 
20PEG8Ac and 10PEG4SH. As per definition, the release rate is therefore independent 
of the initial Hep/HS concentration.153 The rapid release after day 21 can be explained by 
extensive gel degradation.  
 
The release of Hep and HS from Type 2N CI gels (PEG-VS/SH/Hep-Ac and PEG-
VS/SH/HS-Ac) followed first order kinetics, which is expected since only primary 
cleavage of CI Hep/HS from the gel network through hydrolysis, due to the relatively 
labile β-thio-ether ester bond of Hep/HS-Ac with 10PEG4SH, was possible.  The non-
degradable nature of stable thio-ether sulfone linkages between VS and thiols implies 
the absence of secondary ester bonds and therefore the release rate was dependant on 
the Hep/HS concentration.94,153,280 This is consistent with results obtained by 
Bezuidenhout et al. or DuBose et al. who attached dexamethasone via degradable 
linkages to degradable and non-degradable PEG gels213 or incorporated thiolated 
fluorescent probes into acrylated PEG with DTT, respectively.86  
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4.7 Heparin and Heparan Sulfate Activity 
 
The large effect of Hep and HS addition to INTEM assays was expected since, although 
Hep is known to affect both the intrinsic and extrinsic coagulation pathways, it has a 
much greater effect intrinsically due to its function as thrombin amplifier.283 Heparin and 
HS do not have a large effect on either fibrinolysis or the contributions of platelets and 
fibrinogen to final clot strength,259,284 as indicated by fibrinogen ROTEM (FIBTEM) and 
aprotinin ROTEM (APTEM) profiles. It is important to note that although clotting times 
obtained through TEG and ROTEM showed similar trends for both unmodified and 
acrylated Hep/HS, the clotting times obtained through ROTEM were proportionally 
shorter due to more diluted samples used in ROTEM.284 Although native ROTEM 
(NATEM) is not clinically used (long clot formation times due to the lack of initiators),260 it 
was used to evaluate the activity of eluates from Type 2 gels, since the amount of 
Hep/HS incorporated into and released from the gels was very small.  
 
The addition of unmodified Hep to whole blood (WB) led to an expected large increase in 
clotting time (5-6 fold longer than PBS control) due to its well documented 
anticoagulative properties.285,286 A study by Atha et al., for example, showed that the rate 
at which Hep bound antithrombin (AT) III inhibited thrombin increased by two to three 
orders of magnitude.287 The approximately 4 times shorter clotting time of unmodified HS 
(in comparison to Hep) was expected since HS is known to be significantly less anti-
thrombotic. Even though Hoppensteadt et al. found that a five to ten fold higher dose of 
HS was required to produce an equal antithrombotic effect as Hep,14 HS is not 
completely non-antithrombotic since studies have shown that approximately one to ten 
percent of the HS molecules have anticoagulant activity.2,38  The absence in a difference 
between HS and the control can possibly be due to the small concentration of HS added 
making it difficult to observe a significant difference (not due to WB dilution, since the 
control also consisted of WB diluted with PBS).288  Although the activity of Hep was 
slightly compromised after acrylation, it retained its activity to a large extent as the 
clotting time was still significantly longer than that of the PBS control (2-3 fold 
longer).289,290 This decrease in activity after modification was also seen in previous 
studies, where it was shown that the binding affinity of Hep to AT III, after thiolation, 
decreased with increasing functionalization.97  
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The increased clotting times induced by Hep or HS in the eluates indicate the retained 
activity of the Hep/HS during incorporation into and release from Type 1 and 2 gels. 
Eluates from NI gels were active until day 3, while the absence in increased clotting time 
thereafter supports the result that all of the Hep/HS was released from NI gels by day 3.  
Importantly, increased clotting times induced by eluates from CI gels show that the 
released Hep/HS retained activity over the measured elution period. Since the 
concentrations of the eluates were normalised before performing the TEG and ROTEM, 
the differences in clotting times are only based on the activities of the Hep/HS in the 
eluates.  
 
4.8 Growth Factor Binding and Release  
 
Growth factor binding and release experiments were only performed on Type 2D gels.  
Acrylated Hep bound to the PEG gels retained its ability to bind VEGF, since only 0.8 ± 
0.3% of the VEGF initially added was released in the wash-out stage, compared to the 
8.6 ± 1.2 % from controls (PEG gel without bound Hep or HS). This high affinity between 
Hep and VEGF can be ascribed to the presence of Hep binding domains on VEGF.59 
Although HS-Ac was also able to bind VEGF it was to a significantly lesser extent than 
Hep, since Hep has a greater negative charge than HS and therefore promote stronger 
bonds with the net positive charge of VEGF.59,291 Although the Ac groups were in great 
excess over the amount of VEGF added, control gels were able to bind VEGF possibly 
due to the presence of unreacted thiols forming disulfide linkages with the cysteine 
residues of VEGF, as previously reported.7,16   
 
Controlled VEGF release from hydrogels containing Hep-Ac was obtained due to the 
known high affinity of the Hep-VEGF interaction,53,54 which was expected since 
computational and experimental results from previous studies showed that a molar ratio 
of Hep to VEGF of 100:1 was necessary to reduce passive diffusion of GFs from 
hydrogels54 (the ratio in the current study is 150:1). Gels with bound HS were also 
capable of sustained VEGF release, which can be potentially very useful where GF 
binding without strong anticoagulation is desired. The faster GF release rate from the 
bound HS gels can once again be ascribed to the higher affinity between Hep and 
VEGF, in comparison to HS. Both Hep and HS bound PEG gels were able to increase 
the residence time of VEGF, since only 8 to 13% of the initial amount of VEGF were 
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released over a period of 12 days in vitro, while GFs are known to degrade by 
proteolysis within 10–20 min after bolus injection.122,265 Although PEG gels without bound 
Hep/HS could also retain GFs, as shown in previous research7 and by the controlled 
(first order) VEGF release from control gels (PEG-Ac/SH), these gels were not able to 
eliminate the initial VEGF burst release. A study by Wissink et al. had shown that Hep 
hydrogels with Hep:GF molar ratios of 13 000:1 was needed to eliminated burst 
release,35,52,292 but it was however successfully eliminated at a smaller ratio in the current 
study due to the covalent incorporation of Hep/HS into PEG gels. 
 
Failure to release the total amount of GF initially incorporated into the gels has also been 
seen in similar studies by various researchers, but however still led to increased 
angiogenesis in vivo.7,8,16,35,97 This can possibly be attributed to conformational changes 
of GF due to surface adsorption, disulfide exchange between the hydrogels and GF, 
structure loss or the absence of a sequester site during the experimental release period, 
causing it to not be recorded during the ELISA assay.7 Incorporation of VEGF into the 
crosslinked hydrogels could also retard its release leading to a significant fraction of GF 
not released.8,122,265 
 
4.9 In Vivo Evaluation in Rat Subcutaneous Model  
 
The near-complete ingrowth of tissue into the polyurethane (PU) scaffolds (without gel) 
as early as 7 days can be ascribed to the high porosity (82%) and large pores (150 µm 
with 70 µm interconnectivity) of the disks. Various researchers have reported that 
scaffolds with pores of these sizes allow for not only cellular ingrowth, but also 
fibrohistiocytic tissue, capillaries, fibrous tissue and fibro-cartilaginous tissue, ect.293–296 
When the disks are prefilled with any of the hydrogel compositions there is limited 
ingrowth at the early time point, due to presence of the gel.  The increased ingrowth into 
gel-filled scaffolds at day 14 corresponds to the hydrolytic degradation of the ester bonds 
seen in vitro at approximately this time. No correlation was found between the fluctuation 
in ingrowth rate and the presence of Hep/HS.  This agrees with in vitro tests which 
showed that neither covalent nor non-covalent incorporation of Hep/HS significantly 
affected the gelation time, viscoelasticity, swelling or degradation of the gels. Full 
ingrowth achieved for all gel formulations upon gel dissolution agrees with previous work 
showing that Hep containing PEG acrylate gels were able to be degraded and allow cell 
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infiltration within two to four weeks in vivo, depending on the functionalization and gel 
formulation.7–9,203  
 
Collagen deposition by ingrowing cells followed the same trend for the groups containing 
hydrogels, however at lower absolute values, as collagen represents only part of the 
ECM (others include fibrin, laminin and elastin).277  In the case of the non-gel-filled 
scaffolds, the stepwise increase in collagen deposition with increased time may be 
ascribed to a delay between tissue ingrowth and occupation, as well as collagen 
synthesis and deposition.   
 
Disks containing PEG gels (without Hep or GF) formed fewer blood vessels than disks 
without gels (control disks) after 28 days, since the presence of the gel caused a delay in 
tissue ingrowth, while control disks allowed full infiltration (and consequently vessel 
formation) after the first week of implantation.  The slight increase in vascularization of 
disks containing PEG gels with NI Hep in comparison to the PEG gel alone (no Hep) can 
be attributed to the released Hep serving as a sequestration site, stabilizer and 
transporter for GFs present in the local ECM.24,297 However, since most of the NI Hep 
was released during the initial burst the effect was not enough to overcome the initial 
ingrowth inhibition caused by the presence of the gels within a period of 28 days. On the 
other hand, addition of GFs to PEG gels was capable of overcoming this, since a similar 
amount of angiogenesis was achieved for PEG gels with GF and control disks and 
therefore neo-vessels developed during exposure to the active GF.  However, due to the 
short half-life of the GF and the absence of Hep to ensure GF sequestering, the vessel 
numbers only increased while the GF was released - soon after release GFs become 
inactive.9 
 
The addition of CI Hep to the PEG gels did not only overcome the effect caused by the 
retarded angiogenic response due to ingrowth inhibition, but also successfully  improved 
angiogenesis relative to control disks and disks containing PEG gels with GFs.   Due to 
controlled release of Hep (sequestration site, stabilizer and transporter for GFs24,297) GFs 
present in the ECM were localized and concentrated in the scaffold during the entire gel 
degradation and tissue infiltration period, causing an increase in angiogenesis. In a 
previous project performed by our group porous polyurethane scaffolds were 
heparinized and a similar increase in vascularization (after 28 days) had been 
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obtained.245 Most importantly the addition of CI Hep gels with GFs showed the highest 
degree of angiogenesis.  Since the CI Hep was subjected to controlled release during 
degradation and VEGF was sequestered by the released Hep, maximum activity of the 
GF for the longest period of time was ensured, achieving the most profound 
vascularization.  Since the Hep-VEGF complexes are likely to remain in the ECM for 
some time after complete gel dissolution, continued GF release was possibly allowed 
and therefore a continuation of vessel growth, leading to even more angiogenesis.8  
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5 Conclusions 
 
In this study injectable degradable and non-degradable Hep and HS containing PEG 
hydrogels capable of controlled, localized GF delivery were synthesised by utilization of 
PEG chemistries.  These hydrogels showed to be capable of improved angiogenesis in 
vivo. The covalent attachment of α,β-unsaturated groups to Hep and HS were achieved 
by acrylation through the Schotten-Baumann reaction. Controlled and repeatable 
degrees of modification were achieved by controlled addition using a syringe pump and 
product structures were successfully determined by NMR spectroscopy.  
 
Gels formed spontaneously at physiological conditions (37 °C, pH=7.4) by Michael-type 
(1,4 nucleophilic conjugate) addition chemistry, without the need for initiation by 
chemical agents or radiation and without producing leaving groups or undesirable by-
products. Acrylated Hep or HS crosslinked with PEG tetra-thiols (Type 1 gels) were used 
to compare the effect of Hep and HS on gel properties and Hep/HS or GF delivery 
abilities in vitro. The acrylated materials were also copolymerized with degradable 
(acrylate based, 20PEG8Ac) and non-degradable (vinyl sulfone based, 20PEG8VS) 8-
arm PEG macro monomers by reaction with 10PEG4SH (Type 2 gels), which allowed for 
more control over the Hep/HS content and degradation of the gels. Hydrolysis of the 
thio-ether ester crosslinks between Hep/HS-Ac and 10PEG4SH resulted in the release 
of Hep/HS in its original, unmodified form.  
 
Gel properties (gelation times and elastic moduli, hydrogel swelling, crosslink densities 
and mesh sizes) were not significantly influenced by the addition of acrylated Hep/HS. 
Hydrolytic degradation of the cross-linked network of Type 2D gels resulted in 
disintegration after 22 days, while Type 2N gels remained stable for more than 6 
months. The sustained release of the covalently incorporated Hep/HS from Type 2D and 
2N gels followed zero and first order kinetics, respectively (over the 21 and 56 days, 
respectively), which is usually unattainable by simple incorporation and diffusion control 
release mechanisms.86,99,154,155  Type 1 gels also remained stable over the 72 days 
recording period and followed zero order release during that time. It can therefore be 
concluded that controlled, extended and localized release of Hep/HS from the hydrogels, 
copolymerized with 20PEG8Ac or 20PEG8VS (Type 2 gels) or not (Type 1 gels), was 
achieved. 
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The anticoagulative properties of the eluates were successfully decreased by using HS 
instead of Hep. Heparan sulfate is known to be less anti-thrombotic than Hep and this 
property was retained after chemical modification, as well as after the incorporation and 
release from the hydrogels, which is potentially very useful where GF binding without 
strong anticoagulation is desired.  Pro-angiogenic GFs were successfully incorporated 
into Hep/HS containing PEG gels and controlled release of the active GFs was achieved 
and confirmed in vitro by ELISA. Sustained GF release from Hep/HS gels was described 
by zero order kinetics and showed to be more sustained than from pure PEG gels. 
 
In vivo studies in a rat subcutaneous model demonstrated that the hydrogels degraded 
sufficiently after 28 days to allow complete displacement of the gel by tissue to populate 
the PU scaffold interior. The most profound conclusion of this project is that the 
controlled, low and localized delivery of pro-angiogenic GFs (VEGF) from Hep 
containing PEG hydrogels successfully led to an increase in angiogenesis in vivo. 
Although these gels were implanted using PU scaffolds, they have the ability to form in 
situ and spontaneously at physiological pH and temperature by preparing an admixture 
of two components and injecting it directly into the treatment area, thereby avoiding 
invasive surgery.   
 
These encouraging results suggest that the injectable hydrogels developed in this 
project have considerable potential for a spectrum of in vivo cardiovascular tissue 
regeneration applications. In future projects the proven anticoagulative and angiogenic 
GF binding, stabilization and potentiation ability of Hep hydrogels will be evaluated in 
vascular grafts to retain patency, prevent early occlusion through its anti-thrombotic 
properties and to facilitate spontaneous transmural endothelialisation through 
angiogenesis and healing. For the treatment of myocardial infarction and to prevent 
heart failures the GF binding and potential anti-inflammatory properties of heparinoids 
are more important than their anticoagulation properties, and therefore HS containing 
PEG hydrogels may be preferred. In both cases the sustained release of pro-angiogenic 
GFs will be implemented as major driving force of angiogenesis and neovascularization, 
while the covalently attached GAG could further inhibit smooth muscle cell proliferation 
and moderate inflammation. 
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6 Recommendations and Future Directions 
 
• In future more in vivo experiments should also be performed to compare the 
effects between Hep and HS containing PEG hydrogels.    
• The amount and concentration of Hep/HS added to the gels should be optimized. 
It should be high enough to ensure the desired antithrombotic (in the case of Hep 
gels), anti-inflammatory and GF sequestering and activation effects to promote 
neovascularization, whilst not altering the gel properties, cause excessive 
bleeding or haemorrhages. 
• The amount and concentration of GF incorporated into the gels should be 
optimized as well. Large amounts can result in dysfunctional and malformed 
vessels, while too small amounts will not be able to improve healing. The ratio of 
GF and Hep/HS concentrations should also be investigated to optimize their 
activities. 
• The type of GF optimally delivered through Hep/HS hydrogels should be 
investigated, such as bFGF, aFGF, KGF and IGF-1, among others. Due to 
alternative splicing of a single gene, VEGF exists in four isoforms (VEGF121, 
VEGF165, VEGF189 and VEGF206), showing similar biological activities, but 
bind with different affinities to the Hep/HS and can therefore result in different 
secretion patterns.  
• Due to the complexity of angiogenesis the delivery of multiple cytokines 
(delivered simultaneously or in temporally staged sequences) using a single 
intervention, should be investigated. Delivery of two GFs, one chosen for its 
ability to initiate an angiogenic response (e.g. VEGF) and the other for promotion 
of late-stage maturation of newly forming vessels (e.g. KGF), should be 
investigated in the developed hydrogels, which will potentially stimulate different 
stages of micro-vessel growth and lead to the formation of neo-vessel beds 
capable of supporting perfusion. 
• Long-term implantation of PU disk containing hydrogels should be performed to 
follow the healing patterns resulting from continued cellular ingrowth and 
reorganisation. The formulation of the degradable gels (Type 2D) can also be 
altered to obtain gels that degrade at different time points, desired for specific 
applications.  
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• In future studies planned by our research group the GF eluting Hep/HS hydrogels 
will be evaluated in the rat looped infra-renal aortic interposition model for 
thrombogenicity, tissue ingrowth and vascularization, and in the myocardial 
infarction model for myocardial thickness preservation and functional 
improvement. Both in vivo models are established in our laboratories. Clinical 
implementation of these gels in vascular grafts, if successful, have the potential 
to drastically improve the outcome of peripheral small diameter vascular grafts, 
while in myocardial infarction applications they have the potential to reduce left 
ventricular remodelling by increased angiogenesis and cease the progression to 
heart failure. For the latter application the solid content of the gels should be 
investigated for optimum gel formation time, sufficiently rapid to prevent dilution 
of the precursor solutions or encapsulation of specific cell types prior to cross-
linking,81 but also not too rapid to prevent homogeneous mixing or cause an 
increase in the viscosity of the solution, which can jeopardize injection of the 
gel.136,298 
• It would be valuable to perform endothelial cell proliferation assays on GF 
eluates to determine retained activity. In order to avoid GFs becoming inactive in 
the eluates several additives should be investigated to prevent surface 
adsorption during the release period and maintain activity in the release buffer.  
The addition of ethylenediaminetetraacetic acid (EDTA) and sucrose can 
potentially prevent trace metal-induced disulfide exchange between the gels and 
GF and maintain the GF structure in solid state, respectively.  Even the addition 
of Hep to the release medium should be investigated, in order to maintain and 
sequester GF activity after release. 
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7 Research Outputs 
7.1 Conference Presentations 
7.1.1 International Conferences 
 
Heparin and Heparan Sulfate Hydrogels for Cardiovascular Tissue Regeneration 
A Janse van Rensburg, A Oosthuysen, N Davies, LH Callanan, P Zilla, D Bezuidenhout 
POLYCHAR 22 World Forum on Advanced Materials - Poster Presentation 
Stellenbosch, April 2014 
Award: IUPAC Prize Winner   
Heparinized Polyethylene Glycol Hydrogels for Growth Factor Delivery  
A Janse van Rensburg, A Oosthuysen, N Davies, C Chokoza, P Zilla, D Bezuidenhout 
BIO ENG’14 International Conference - Poster Presentation 
Istanbul, November 2014 
 
7.1.2 Local Conferences 
 
Heparinoid Hydrogels for Cardiovascular Applications  
A Janse van Rensburg, A Oosthuysen, N Davies, LH Callanan, P Zilla, D Bezuidenhout 
University of Cape Town Research Day - Talk 
Cape Town, November 2013 
Injectable Heparin and Heparan Sulfate Hydrogels for Cardiovascular Tissue 
Regeneration  
A Janse van Rensburg, A Oosthuysen, N Davies, LH Callanan, P Zilla, D Bezuidenhout 
2014 UCT Postgraduate Research Week - Poster Presentation 
Cape Town, May 2014 
Award: McKinsey & Company Prize Winner (Health Sciences and Science)  
 
7.2 Intended Journal Submission 
 
Growth Factor Delivery from Covalently Heparinized Polyethylene Glycol 
Hydrogels for Improved Tissue Engineering Scaffold Vascularization  
A Janse van Rensburg, A Oosthuysen, C Chokoza, N Davies, P Zilla, D Bezuidenhout 
Biomacromolecules   
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9 Appendices 
9.1 Appendix A - Standard solutions 
9.1.1 Phosphate Buffered Saline  
 
In this project two different forms of phosphate buffered saline (PBS) were used. 
Phosphate buffered saline formula 1 (PBS1) was used as supernatant during the 
swelling, drug elution and in vitro drug activity experiments, while phosphate buffered 
saline formula 2 (PBS2) was used as solvent during gelling through conjugate addition 
since it has a higher buffering capacity than PBS1.  
 
PBS1 (sterilized, pH = 7.4) was prepared by dissolving disodium hydrogen phosphate 
(Na2HPO4·12H2O, 2.89 g, 8.1 mmole), potassium dihydrogen phosphate (KH2PO4, 0.2 g, 
1.5 mmole), potassium chloride (KCl, 0.2 g, 2.7 mmole) and sodium chloride (NaCl, 8 g, 
136.9 mmole) in 1 L deionised water (DI)  
 
PBS2 (sterilized, pH = 7.4) was prepared by mixing solution A (65 mL), solution B (435 
mL) and solution C (500 mL). Solution A: sodium dihydrogen phosphate (NaH2PO4·H2O, 
0.15M, 5.175 g, 15.0 mmole, 250 mL DI); Solution B: disodium hydrogen phosphate 
(Na2HPO4·12H2O, 0.15M, 13.425 g, 75.0 mmole, 250 mL DI); Solution C: sodium 
chloride (NaCl, 0.15M, 4.383 g, 77.0 mmole, 500 mL DI). 
 
9.1.2 Fixatives  
 
In this project two different fixatives were used, 10% Formalin and Zinc fixative. Formalin 
fixative (10%) was prepared by dissolving sodium chloride (42.5 g), disodium hydrogen 
phosphate (6.4 g) and sodium dihydrogen orthophosphate anhydrous (0.7 g) in 5 L DI.  
The pH was adjusted to 7.6, formaldehyde (500 mL, 40%) was added and the fixative 
was stored at 4 °C. The Zinc fixative was prepared by dissolving calcium acetate (0.5 g), 
zinc acetate (5 g) and zinc chloride (5 g) in Tris buffer (0.1M, 1000 mL, pH = 7.4) and 
stored the fixative at RT.             
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9.2 Appendix B – Nuclear Magnetic Resonance Spectra 
 
 
Figure 44: 1H NMR spectrum of 20PEG8Ac 
 
 
Figure 45: 1H NMR spectrum of 20PEG8VS 
H-(O-CH2-CH2)n-OH (PEG) 
PEG 
ppm 
ppm 
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Figure 46: 13C NMR spectra of Hep (above) and Hep-Ac (below)  
 
 
Figure 47: 13H NMR spectra of HS, HS-Ac, Hep and Hep-Ac 
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ppm 
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Figure 48: COSY NMR spectrum of Hep 
 
 
Figure 49: COSY NMR spectrum of Hep-Ac 
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ppm 
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Figure 50: HSQC NMR spectrum of Hep 
 
Figure 51: HSQC NMR spectrum of Hep-Ac   
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Figure 52: TOCSY NMR spectrum of Hep-Ac   
 
Figure 53: HMBC NMR spectrum of Hep-Ac  
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